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Development and application of the Landing Pad platform: A synthetic 




To accelerate the construction of superior yeast strains producing high-value chemicals, we 
developed a modular CRISPR/Cas9 integration platform in S. cerevisiae that accommodates 
marker-less, multi-copy gene integration. Our engineering strategy introduced a series of synthetic 
DNA parts, called Landing Pads (LP), into the S. cerevisiae genome to act as modular anchors 
for heterologous gene integrations. The LPs have been designed to accommodate the 
CRISPR/Cas9 genome editing system and to facilitate multi-copy gene integration of one, two, 
three and four copies in a single step. First we designed ten synthetic gRNA targeting sequences 
and evaluated their targeting specificity, integration efficiency, and possible off-target effects. We 
also surveyed 16 genomic loci for landing pad integration by evaluating the integration efficiency 
and gene expression profiles at each site. The results gleaned from our preliminary tests informed 
the final configuration of the LP platform strain. To demonstrate the utility of our LP integration 
system, we used the platform to screen ten variants of norcoclaurine synthase (NCS), a 
notoriously inefficient enzyme that catalyzes the first committed step in the production of high-
value benzylisoquinoline alkaloids (BIA). The platform enabled rapid integration of each NCS 
variant in one, two, three and four copies in parallel, yielding 40 strains total. LC/MS analysis 
identified two variants, NdNCS and ScNCS that produce higher concentrations of the BIA scaffold 
(S)-norcoclaurine by increasing copy number, suggesting that the proposed strategy may help 
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1.1. Yeast Cell Factories 
Engineering microbes into cellular factories is a rapidly growing field of biotechnology that 
has broad applications within the energy, agriculture and human health sectors. Advances in DNA 
sequencing and synthesis technologies and the development of genome-editing tools have 
enabled us to rationally engineer microorganisms in order to produce bio-based fuels, chemicals 
and pharmaceuticals from renewable feedstocks [1-4]. The yeast Saccharomyces cerevisiae is a 
common industrial microbe traditionally used for ethanol fermentation and leavening bread. As 
such, S. cerevisiae is a preferred host for producing fuels and chemicals due to its GRAS 
(generally regarded as safe) status, high stress tolerance and general robustness for industrial 
fermentation [1, 2]. The availability of genetic tools and genetic tractability of S. cerevisiae also 
benefits metabolic engineering efforts towards the synthesis of high-value compounds [5-7]. In the 
last decade, S. cerevisiae has been successfully engineered for commercial production of high-
value chemicals, including isobutanol and farnesene, as well as the anti-malarial drug artemisinin 
[4]. However, the vast majority of metabolic engineering efforts in S. cerevisiae have remained 
‘proof-of-concept’, and have a long way to go before they achieve commercial viability with regard 
to titer, yield and productivity [8]. 
 
Engineering yeast cell factories to synthesize non-native compounds involves 
reconstituting heterologous pathways, as well as modifying native metabolic processes. The first 
step in the production of new biocompounds is to characterize the biosynthetic pathway of the 
target compound from the source organism. Once the target pathway has been elucidated, genes 
encoding the respective enzymes are either isolated directly from the host or synthesized as 
synthetic DNA [9, 10]. In yeast, pathway genes are assembled into individual expression cassettes 
and then introduced to the host on episomal plasmids or integrated directly into the chromosome. 
Initial proof-of-concept strains typically only produce small amounts of the target compound. This 
is because production hosts have evolved to prioritize native metabolic processes or the 
heterologous pathway does not function well in the non-native host [11]. Therefore, achieving 
commercially viable production strains often requires extensive pathway troubleshooting and 
optimization. As the design-build-test cycle for achieving industrially-relevant yeast strains is slow, 
labor-intensive and expensive. As such, researchers are continuously searching for new 
strategies that accelerate the construction of superior yeast strains. 
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1.2. Pathway optimization 
Pathway optimization is an iterative process that typically involves many cycles through the 
design-build-test pipeline. After the initial proof-of-concept has been implemented, pathway 
bottlenecks are identified and targeted for optimization. Pathway bottlenecks are caused by 
enzyme inefficiencies or low substrate availability that limit flux through the pathway, resulting in 
low product yields [10, 12]. In order to enhance flux towards the target metabolite, a number of 
genetic optimization strategies have been implemented to improve enzyme activity and balance 
enzyme expression levels. 
 
Enzyme bioprospecting 
A common approach to overcome enzyme inefficiencies is to screen for improved catalytic 
activity from a library of orthologous enzyme variants. The wealth of publicly available ‘omics’ data 
has enabled us to mine transcriptome databases and select candidate genes encoding enzymes 
with the same putative function [9, 10, 13]. Using a plug-and-play strategy, each enzymatic 
conversion step in a pathway can be optimized by identifying variants with improved catalytic 
efficiency and substrate specificity. The reduced cost of DNA synthesis has made it easier to 
obtain genetic material by purchasing synthetic gene sequences rather than isolating and 
compiling variants from multiple sources [9, 10]. This also enables us to codon-optimize 
heterologous gene sequences for improved expression in S. cerevisiae, which further enhances 
flux through the target pathway [14, 15]. 
 
Enzyme expression levels 
Controlling heterologous gene expression in multi-enzyme pathways is important for 
balancing flux and preventing the accumulation of side-products and toxic intermediates [10]. 
Genetic tuning involves the application of simple genetic tools to enhance or control gene 
expression in order to increase flux towards the target compound [16]. Regulating gene 
transcription is the primary method for balancing flux through a pathway and is controlled by 
swapping regulatory elements or titrating gene copy number. For instance, tuning gene expression 
can lead to six-fold differences in enzyme activity between promoters [17] and a 70-fold difference 
between terminators [18]. A large collection of regulatory elements has been characterized in 
yeast [19, 20],  thus providing a diverse toolkit to optimize production of biosynthetic enzymes [6]. 
Strong constitutive promoters and expression-enhancing terminators are regularly chosen for 
pathway engineering to maximize the expression of biosynthetic genes [16]. 
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Gene copy number 
Titrating the copy number of the corresponding biosynthetic gene can further enhance 
enzyme levels. This strategy can be applied to an entire metabolic pathway to increase overall 
product yield [21], or targeted to specific enzymes to overcome pathway bottlenecks. Increasing 
gene copy number often enhances transcriptional levels, which can produce more enzyme and 
increase substrate turnover [22, 23], at least up to a certain limit [24]. However, modulating gene 
copy number may also be futile for some enzymes [25], and in some cases, can have detrimental 
effects on productivity and growth rate due to the build-up of toxic intermediates [26]. For these 
reasons, it is more prudent to optimize gene copy number for each enzyme individually to prevent 
deleterious effects and to avoid placing an unnecessary burden on the cell. 
 
Modulating gene copy number is carried out by expressing the target gene from a multi-
copy plasmid or by integrating one or more times into the host chromosome. Plasmid-borne 
expression is an efficient strategy to test a wide-range of expression levels in yeast by selecting 
one of two commonly-used expression vectors: i) low-copy CEN plasmids (1-2 copies per cell) or 
ii) high copy 2µ plasmids (10-50 copies per cell) [27]. However, the exact plasmid copy number 
for any given cell in a population is highly variable, and so plasmid-based systems offer limited 
control over fine-tuning gene dosage. Ryan et al. (2014) demonstrated that even for genes 
expressed from a low-copy plasmid, expression levels between individual cells were highly 
variable as well. Plasmid-based systems are also problematic for industrial use because cells 
must be propagated in selective media, and even then, plasmids could be lost or rearranged over 
long-term cultivation [2, 29]. To avoid these challenges, chromosomal integration is the preferred 
strategy for expressing heterologous genes, and also enables the fine-tuning of gene copy 
number, which could be critical for balancing metabolic pathway fluxes. Nevertheless, integrating 
multiple genes into the chromosome is a laborious process, and often necessitates iterative 
rounds of gene integration. 
 
1.3. Genome editing in S. cerevisiae 
Integration into the S. cerevisiae genome is achieved by harnessing the yeast homologous 
recombination (YHR) machinery [30-33]. This is accomplished by flanking the genetic construct 
and selection marker with site-specific homology arms, which then recombine with the 
homologous sequence at the genomic integration site. While homologous recombination (HR) is 
a relatively simple technique for integrating and assembling heterologous DNA, it suffers from low 
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integration efficiencies, even when selection is applied [34]. It was later demonstrated that 
integration efficiency using YHR dramatically improves when a double-strand break (DSB) is 
induced at the integration site [34, 35], which initiates homology-directed repair (HDR) using the 
exogenous DNA fragment. Several endonucleases have since been identified that induce targeted 
DSBs, including Zinc-Finger Nucleases (ZFN) [36], Transcription Activator-Like Effector 
Nucleases (TALEN) [37] and Clustered Regularly Interspaced Short Palindromic Repeats  
(CRISPR) with CRISPR-associated (Cas) proteins [38, 39]. While all three systems employ 
programmable endonucleases to induce targeted DSBs, the CRISPR/Cas system has become 
the preferred genome-editing tool, offering more customizability and multiplexing capabilities. 
 
CRISPR/Cas9-mediated genome editing 
CRISPR/Cas is a bacterial defense system [38, 40, 41] that has recently been adapted into 
a powerful genome editing tool [38]. The type II CRISPR/Cas9 system from the bacterial species 
Streptococcus pyogenes is the most common CRISPR/Cas system that has been harnessed for 
targeted genome engineering in bacteria [42], yeast [39], plants [43, 44], and animals [45-47]. The 
CRISPR/Cas9 system has two main components, the RNA-guided Cas9 nuclease that cleaves 
dsDNA, and a programmable guide RNA (gRNA) that directs Cas9 to a specified target site [38]. 
The only prerequisite for achieving targeted Cas9-mediated DSBs is the presence of a Cas9 
binding signal 5'-NGG-3', known as the protospacer adjacent motif (PAM), which can be found 
virtually anywhere in the genome [38, 45, 48]. Once the genomic target site is defined by the user, 
a 20-nucleotide site-specific ‘targeting’ sequence is programmed into the gRNA, which guides 
Cas9 to the complementary sequence upstream of the PAM. The Cas9-gRNA complex then binds 
to the target site, triggering DNA unwinding and Cas9-mediated DSB formation [49]. Following 
DSB induction, native HDR machinery is initiated in the presence of a DNA repair template, 
resulting in targeted integration of exogenous DNA without the need for selection [39]. 
 
CRISPR/Cas9 enables scar-less, marker-free genome editing with high efficiency and 
fidelity in S. cerevisiae [39]. By expressing multiple gRNAs to target different regions of the 
genome, the CRISPR/Cas9 system also supports multiplex engineering strategies [45, 50]. This 
has greatly increased the efficiency of pathway reconstruction and optimization by reducing the 




Multiplexed CRISPR/Cas9 genome engineering strategies in S. cerevisiae 
The CRISPR/Cas9 genome editing system was first demonstrated in S. cerevisiae by 
DiCarlo et al. (2013), who successfully performed a single gene knock-out and knock-in using 90 
bp double-stranded oligonucleotides (dsOligos) for HDR of the Cas9-mediated DSB. Since then, 
many different CRISPR/Cas9-based strategies have emerged that have improved the efficiency 
of targeted genome editing and expanded the CRISPR/Cas9 genome-editing toolbox. Ryan et al. 
(2014) modified the gRNA architecture by fusing the gRNA to the 3' end of a self-cleaving 
ribozyme, which enhanced intracellular gRNA levels and facilitated targeted integration of a three-
part DNA assembly at a single locus. Bao et al. (2014) developed a multiplexed CRISPR/Cas9 
strategy designed to disrupt three different genes in a single reaction by introducing frameshift 
mutations with a 100 bp ‘heterology block’. Horwitz et al. (2015) established a multiplexed 
CRISPR/Cas9 strategy for integrating an entire biochemical pathway by introducing separate DNA 
fragments containing multiple genes into the S. cerevisiae genome at three separate loci. The 
multiplexed CRISPR/Cas9 integration strategies developed by Ronda et al. (2015) and 
Jakočiūnas et al. (2015) applied the EasyClone system for simultaneous CRISPR/Cas9-mediated 
integration into the User sites.  Ronda et al. (2015) reported the highest integration efficiencies for 
multiplexed integration of three large 8 kb DNA constructs, while Jakočiūnas et al. (2015) achieved 
a 5-part in vivo assembly at three separate loci. Finally, by targeting delta (δ) sequences of Ty 
retrotransposons, Shi et al. (2016) successfully integrated up to 18 copies of a 24 kb xylose 
utilization and (R,R)-2,3-butanediol (BDO) production pathway in a single assay, though copy 
number and integration loci were not controlled. 
 
1.4. Landing Pad platform 
The majority of multiplexed CRISPR/Cas9 engineering strategies that have been initiated 
in S. cerevisiae have concentrated on the pathway construction process [21, 53-55] or the 
simultaneous disruption of multiple native genes [28, 52, 56]. To expand the multiplexed 
CRISPR/Cas9 toolbox, the goal of this study was to develop a novel method to advance the strain 
optimization process. To this end, we implemented a multiplexed CRISPR/Cas9 integration 
platform in S. cerevisiae that facilitates marker-less, multi-copy gene integration in a single step. 
Our strategy was designed to simplify enzyme library screens and test whether modulating gene 




Project overview  
The Landing Pad (LP) platform is a CRISPR/Cas9 integration system built into the  
S. cerevisiae genome that uses synthetic DNA parts, called Landing Pads (LP), to facilitate multi-
copy gene integrations (Figure 1). The LP platform is comprised of four distinct LPX constructs 
(LP1, LP2, LP3, LP4) that were inserted throughout the yeast genome at different copy numbers. 
Each LP contains a unique 5'-N20NGG-3' gRNA target sequence flanked by two recombinogenic 
regions, and are used as anchors to accommodate CRISPR/Cas9-mediated gene integration 
(Figure 2). The number assigned to each LPX represents their genomic copy number motif within 
the LP platform strain, i.e. the number of times the LPX was inserted into the S. cerevisiae genome; 
LP1 was inserted at one locus, LP2 was inserted at two loci, LP3 was inserted at three loci and 
LP4 was inserted at four loci. Since each LPX within the same motif contains identical target sites 
and recombinogenic regions, a single gRNA and donor construct are used for CRISPR/Cas9-
mediated gene integration. In other words, the LPX motifs act as modular target sites for multi-




Figure 1. Schematic overview of the CRISPR/Cas9 Landing Pad platform in S. cerevisiae. 
(A) Landing pad construct. A synthetic block of DNA integrated into the yeast genome that serves as a 
modular anchor for CRISPR/Cas9-mediated gene integration. Consists of modular parts: a target site (5'-
N20CGG-3') for guiding CRISPR/Cas9 endonuclease activity and LP.A and LP.Z recombinogenic regions 
(~250 bp) for gene integration via HDR of Cas9-induced DSBs using donor DNA flanked by A/Z homology 
arms. (B) S. cerevisiae landing pad platform. The platform consists of four distinct landing pads (LP1, LP2, 
LP3, LP4) integrated into 10 different genomic loci.  Each landing pad contains a synthetic target site paired 
with a unique set of recombinogenic anchors. The LPX number corresponds to the number of copies of each 




Figure 2. CRISPR/Cas9-mediated gene integration into a landing pad 
Targeted integration into the landing pad platform begins by co-transforming a linear Cas9 vector and  
LP-gRNA cassette with a gene construct flanked by LP.A/LP.Z homology arms. Upon transformation, the 
LP-gRNA cassette and Cas9 vector backbone assemble into a circular expression vector via gap repair. 
The Cas9 and LP-gRNA form a ribonucleoprotein complex that is directed to the landing pad by the 5'-
N20CGG-3' targeting sequence of the LP-gRNA. Cas9 endonuclease activity is initiated upon recognition of 
the PAM (NGG), creating a DSB at the LP target site. The gene construct repairs the DSB through HDR, 
which restores the chromosome upon integration into the LP site. 
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Summary of the work done in this study  
To construct the LP platform strain, we first designed the synthetic LP constructs and  
N20-gRNA target sequences in silico, and performed a number of preliminary tests to optimize 
performance of the LP integration system. Previous work has shown that the N20-gRNA targeting 
sequence is one of the most important parameters for successful CRISPR/Cas9-mediated DSB 
induction [39, 57]. Generally, the gRNA targeting sequence should be between 17-20 nucleotides 
long and contain 40-80% GC content [58]. While some additional gRNA design criteria have been 
reported [45, 59, 60], it is difficult to predict the functionality of a gRNA before it is evaluated in 
vivo. For this reason, we generated ten synthetic N20-gRNA candidates and evaluated their fidelity 
towards the complementary LP target site in vivo. We also compared integration efficiency and 
gene expression profiles of 16 genomic loci that were selected from previous work [61, 62]. This 
was to verify that genomic sites assigned to the LP platform were i) susceptible to Cas9-mediated 
DSB induction, and ii) showed similar transcription levels for titrating gene expression. The results 
obtained from the preliminary tests informed the final configuration of the LP platform. After the 
platform was built into S. cerevisiae, we optimized the efficiency of multi-copy gene integration 
into each LP copy number motif, and showed that gene expression levels are proportionate to 
gene copy number. As proof-of-concept, we then applied the LP platform strategy to help alleviate 
a key pathway bottleneck towards the synthesis of benzylisoquinoline alkaloids in S. cerevisiae. 
 
1.5. Benzylisoquinoline alkaloids 
Benzylisoquinoline alkaloids (BIA) are a diverse class of plant secondary metabolites 
largely known for their important pharmaceutical properties. The most notable BIAs include the 
analgesics morphine and codeine, the antitussive and anti-cancer agent noscapine, the 
vasodilator papaverine, and the antimicrobial agents berberine and sanguinarine [63, 64]. With 
over ~2500 BIAs identified, only a small fraction have been clinically tested, and an even smaller 
fraction are commercially available [64]. Despite their therapeutic potential, many of these 
compounds remain understudied because they are only found in trace amounts in the source 
plant, which makes extraction processes too inefficient and costly for drug development [65]. Even 
for compounds that are currently produced at large scales, cultivation of the source plant is 
laborious and resource-intensive, and the supply is vulnerable to environmental degradation and 
climate change [10, 63, 64]. These conditions have motivated research into alternative BIA 
production platforms, namely microbial synthesis, in order to scale-up the production of low-
yielding BIAs and secure the supply of commercially available medicines [9, 10, 64-68]. Microbial 
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factories also provide a more efficient platform for the discovery of new BIA molecules with novel 
biological activities [10, 64]. 
 
BIA biosynthesis in S. cerevisiae 
The characterization of enzymes involved in BIA synthesis from the opium poppy (Papaver 
somniferum), as well as other BIA-producing plants, has facilitated the reconstitution of several 
BIA pathways in S. cerevisiae towards the production of (S)-reticuline [69], sanguinarine [66], 
morphine and codeine [68]. Early efforts focused on the reconstitution of partial BIA pathways as 
proof-of-concept, which synthesized downstream BIAs from intermediate substrates provided in 
the growth media. However, construction of industrially relevant strains requires that BIAs are 
synthesized de novo from simple carbon sources rather than expensive intermediates, which 
involves connecting BIA metabolism to primary yeast metabolism. 
 
Entry into BIA metabolism begins with the synthesis of (S)-norcoclaurine, the central 
scaffold from which all BIAs originate [70-72]. Synthesis of (S)-norcoclaurine in S. cerevisiae 
requires heterologous expression of norcoclaurine synthase (NCS), which catalyzes the 
enantioselective Pictet-Spengler condensation of dopamine and 4-hydroxyphenylacetaldehyde 
(4-HPAA) to produce (S)-norcoclaurine [71, 72]. Since dopamine and 4-HPAA are both derived 
from the aromatic amino acid L-tyrosine, BIA metabolism connects to yeast central metabolism 
via the aromatic amino acid (AAA) pathway. Unfortunately, entry into BIA metabolism in  
S. cerevisiae is very inefficient, due in part by the low catalytic activity of NCS [73, 74], as well as 
the low intracellular availability of substrates 4-HPAA and dopamine [64, 75]. This represents the 
first rate-limiting step towards the synthesis of BIAs in S. cerevisiae and is the major pathway 
bottleneck. Until we can improve the production of (S)-norcoclaurine, synthesis of downstream 
BIAs in yeast will remain proof-of-principle. 
 
Previous efforts to improve the production of (S)-norcoclaurine in S. cerevisiae have 
focused on increasing substrate availability and improving NCS enzyme efficiency. De novo 
production of (S)-norcoclaurine in S. cerevisiae was first achieved by Deloache et al. (2015), who 
introduced a tyrosine hydroxylase and a DOPA decarboxylase into S. cerevisiae to generate 
dopamine from tyrosine via the intermediate L-DOPA. They also increased the availability of 
tyrosine by overexpressing a feedback-insensitive mutant of the L-tyrosine pathway enzyme 
ARO4, which more than doubled the production of dopamine. With their improved dopamine 
production strain, Deloache et al. evaluated three different NCS variants and identified an NCS 
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variant from P. somniferum (PsNCS3) that produced the highest recorded (S)-norcoclaurine titer 
at 104.6 µg/L. Similar work done by Trenchard et al. (2015) also improved flux towards tyrosine in 
S. cerevisiae before testing different NCS variants, though they only generated ~5-10 µg/L (S)-
norcoclaurine from de novo synthesis. 
 
1.6. Application of the LP platform to improve entry into BIA metabolism 
Compared to other enzymes involved in BIA metabolism, the NCS variant from Thalictrum 
flavum demonstrates low substrate affinity and a catalytic efficiency that was reportedly 100-fold 
lower than the average across all enzymes [73]. In order to improve (S)-norcoclaurine production, 
and by extension the production of all BIAs, it is necessary to identify a better NCS variant. It has 
also been shown that some NCS variants from the Papaveraceae family occur as natural fusion 
proteins consisting of up to four repeated domains [74]. This finding is interesting because 
enzymes with more repeated domains demonstrated higher catalytic efficiency than those with 
fewer domains [74], which suggests that the activity of single-domain NCS variants could also be 
improved by increasing gene copy number. Taken together, these circumstances provide an ideal 
opportunity to apply the LP platform to efficiently 1) screen a library of NCS variants to identify a 
superior enzyme variant and 2) test whether increasing the gene copy number produces higher 
titers of (S)-norcoclaurine from single domain NCS variants. 
2. MATERIALS & METHODS 
2.1. Strains & Media 
Yeast 
S. cerevisiae strains built in this study were constructed using the parent strain CEN.PK2-
1D and are listed in Appendix Table A1. Yeast cultures were grown in YPD (10 g/L yeast extract, 
20 g/L tryptone, 20 g/L dextrose (Thermo Fisher Scientific), YPS (10 g/L yeast extract, 20 g/L 
peptone 40 g/L sucrose) or synthetic complete (SC) medium made with 6.8 g/L Yeast Nitrogen 
Base (YNB) without amino acids, 1.92 g/L SC (-histidine), 0.76 mg/L L-histidine (Sigma Aldrich) 
and supplemented with 4% glucose. When appropriate, 200 µg/ml of geneticin (G418) (Sigma 





Escherichia coli cultures were cultivated in Lysogeny Broth (LB) (Sigma Aldrich) 
supplemented with either 50 µg/ml kanamycin (Sigma Aldrich) or 100 μg/ml ampicillin (Sigma 
Aldrich) where applicable and grown overnight at 37°C with shaking at 200 rpm. 
 
2.2. DNA Manipulation 
Plasmids 
All plasmids used in this study are listed in Appendix Table A2 and were maintained in E. 
coli DH5α. The pCAS plasmid was purchased from Addgene (Plasmid #60847). Selected 
constructs were cloned into plasmid pJet1.2 using the CloneJet PCR cloning kit (Thermo Fisher 
Scientific). The gfp expression cassette was amplified from pGREG503 [76]. Genes required for 
dopamine synthesis were amplified from the yeast integration plasmid (YIP) pWCD2249 
(Genbank KR232306.1). NCS variants were amplified from pBOT(HIS) [10]. Plasmids were 
purified from E. coli stocks using the GeneJET plasmid mini prep kit (Thermo Fisher Scientific). 
 
Landing Pads 
Synthetic recombinogenic regions were designed using the random DNA sequence 
generator FaBox [77] with 50% GC content and then queried against the S. cerevisiae genome to 
ensure no sequence similarity was found with the native DNA. Four Landing Pads were 
synthesized as 560 bp gBlocks (Integrated DNA Technologies) (Appendix Table A3). Synthetic 
gRNA targeting sequences (N20) were generated using >40% GC cut-off and queried against the 
S. cerevisiae genome. Ten gRNA targeting sequences (Table 1) were selected for preliminary 
testing and synthesized as oligonucleotides. Complementary target sites (5'-N20CGG-3') were also 
synthesized as oligonucleotides.  
 
Primers used in this study are listed in Appendix Tables A4-A14. DNA constructs were 
amplified by PCR using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific). 
Linearized DNA fragments were isolated using 0.8% (w/v) agarose gel electrophoresis and 





Linearization of pCAS plasmid 
The pCAS vector backbone and the pCAS gRNA expression cassette were amplified with 
overlapping homology regions using the primers listed in Appendix Table A4. To program novel 
targeting sequences, the expression cassette was amplified in two universal parts: Left (tRNATyr-
3'HDV) and Right (scaffold-TSNR52) using primers that insert overlapping sequence containing the 
novel N20Target sequence. The two parts were then reassembled in a second PCR to generate 
the full-length gRNA cassette. The (–gRNA) expression cassette was generated by fusing the left 
and right gRNA fragments together using overlapping primers. Primers used to program synthetic 
gRNAs are listed in Appendix Table A5. Primers used to program the gRNAs targeting the  
S. cerevisiae genome are listed in Appendix Table A6. 
 
Landing Pad Constructs 
To generate the LP.A and LP.Z recombinogenic regions, the LP gBlock sequences were 
amplified in two equal parts using primers listed in Appendix Table A7. To build the LP1 constructs 
harbouring target sites T1-T10, the LP1.A and LP1.Z regions were amplified using overlapping 
internal primers that contain the 10 x synthetic 5'-N20CGG-3' gRNA target sites (Appendix Table 
A8). To evaluate the synthetic gRNAs, full-length LP1.TX constructs were amplified with primers 
that attach ~50 bp flanking homology to the FgF20 locus. To evaluate CRISPR/Cas9-mediated 
gene integration at selected genomic loci, the LP1.T3-SiteX constructs were amplified with primers 
(Appendix Table A9) to attach homologous arms complementary to each genomic integration site 
(Table 2). To integrate LP constructs into the genome, we amplified the ‘up’ and ‘down’ regions of 
each FgF locus [61] from CEN.PK2-1D genomic DNA and fused them to LP1.T3 by OE-PCR, 
generating 15 LP1.T3-SiteX constructs. To integrate the LP1.T3 construct into USERXII-1, LP1.T3 
was amplified with primers that attach ~60 bp flanking homology to the USERXII-1 locus. Primers 
to amplify up and down genomic regions are listed in Appendix Table A10. 
 
LP donor DNA 
LP donor DNA constructs were generated by PCR using primers listed in Appendix Table 
A11. For integration efficiency tests in CEN.LP the gfp expression cassette (PTDH3-gfpS65T-TCYC1) 
was amplified from pGREG503 plasmid (GC975) using primer pairs to attach 60 bp flanking 
homology to LP1, LP2, LP3 and LP4. To generate gfp donors with full-length homology to the LP 
recombinogenic regions, LPX.A and LPX.Z regions were amplified from the CEN.LP genome and 
then fused to the LPX.gfp donor DNA with 60 bp overlap by PCR. The full-length LPX.gfp donor 
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constructs were cloned into the pJET1.2 vector and used as template for future amplifications. 
NCS variants (PTEF1-NCSX-TPGI1) were amplified from the corresponding pBOT vector using primer 
pairs to attach ~60 bp flanking homology to LP1, LP2, LP3 and LP4. 
 
Dopamine production cassette 
The dopamine expression cassette (PTDH3-CYP76AD1
W13L_F309L-TTDH1-PCCW12-DODC-TADH1-
PPGK1-ARO4
FBR-TPGK1) was amplified from pWCD2249 [75] in two overlapping fragments with 
~60bp flanking homology to the ARO4 locus (Appendix Table A12). 
 
2.3. Yeast Transformation 
S. cerevisiae was transformed using a method modified from the Gietz PEG/LiAc protocol 
[78]. Strains were grown overnight in YPD medium at 30°C with shaking and then diluted to an 
optical density at 600 (OD600) of 0.175 into fresh 2xYPD and propagated at 30°C with shaking until 
the culture reached OD600 0.6-0.8. Cells were harvested and washed once with water followed by 
a second wash in 100 mM lithium acetate. The cell pellet was then suspended again in 100 mM 
lithium acetate (20 µl per transformation) before adding the transformation mix, which included 
per reaction: 100 µL 50% (w/v) PEG3350, 5.6 µL 3M lithium acetate, 4.4 µL boiled salmon sperm 
DNA (10 mg/ml), and 20 µl DNA + water. Transformation conditions included a 30 min incubation 
period at 30°C, followed by a 30 min heat shock at 42°C. Cells were recovered overnight in 500 
µL YPD before plating on selective medium containing G418 or hygromycin to maintain the pCAS 
plasmid. For transformations requiring an extended outgrowth in selective medium, recovered 
cells were diluted 1:100 into fresh YPD+G418 medium, and grown for 48h at 30°C with shaking 
before plating on YPD+G418 medium. 
 
2.4. CRISPR/Cas9-mediated genome integration 
All genomic integrations were performed using the CRISPR/Cas9 delivery system 
developed by Ryan et al. (2014), which delivers cas9 and gRNA on a single 2µ plasmid (pCAS). 
In pCAS the cas9 gene from Streptococcus pyogenes fused to a yeast nuclear localization signal 
and expressed using a medium strength RNR2 promoter (PRNR2-cas9_NLS-TCYC1). The tyrosine 
RNA II polymerase promoter and SNR52 terminator are used for expressing the gRNA, which is 
fused to the 3' end of a self-cleaving HDV ribozyme (tRNATyr-3'HDV_N20Target_scaffold-TSNR52). 
The pCAS plasmid encodes the kanMX selection marker which allows growth in media containing 
G418. 
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The pCAS plasmid is assembled in vivo by homologous recombination between two 
overlapping linear fragments: pCAS vector backbone harbouring cas9 (250 ng) and the gRNA 
expression cassette (400-800 ng). Homology arms attached to any donor DNA construct were 
designed so that the gRNA target site would be replaced upon integration. Between 1-4 µg of 
donor DNA was used for CRISPR/Cas9-mediated integration. 
 
2.5. Strain Construction 
Construction of LP1.TX strains 
To test the targeting specificity and integration efficiency associated with the synthetic 
gRNAs, we first had to introduce the LP1 construct harbouring the complementary target sites 
(LP1.TX) into the S. cerevisiae genome. The FgF20-LP1.TX constructs (x10) were integrated 
separately into the CEN.PK2-1D strain at the FgF20 locus by co-transforming cas9 with either 
FgF20-gRNA1 or FgF20-gRNA2 (Appendix Table A6). Upon transformation, a Cas9-mediated 
DSB was generated within the FgF20 “deletion region” (Table 2). FgF20-LP1.TX constructs with 
flanking up/down homology to the FgF20 locus repaired the DSB through HDR, which replaced 
the deletion region upon integration. LP1.Tx integration were confirmed by colony PCR using 
primers that amplify the 5' and 3' genomic DNA flanking LP1 (Appendix Table A13). Positive 
integrant colonies were sequence verified and cultured for two days in YPD to remove the pCAS 
plasmid. The LP1.TX strains were then saved in 15% glycerol and stored at -80°C. The strains 
were streaked onto YPD to obtain single colonies for subsequent testing of the synthetic gRNAs. 
 
Construction of LP1.T3. SiteX strains 
To compare integration efficiency and gene expression levels at various genomic loci in S. 
cerevisiae, we first introduced the LP1.T3 construct at 16 genomic loci we selected based on work 
by Flagfeldt et al. (2009) and Mikkelsen et al. (2012). Sixteen LP1.T3 donors were generated by 
fusing ~500 bp homology arms for each genomic locus. LP1.T3 constructs were introduced into 
the CEN.PK2-1D strain at the corresponding locus by co-transforming cas9 with site-specific 
gRNA(s) listed in Appendix Table A6. Upon transformation, the LP1.T3 construct replaces the 
“deletion region” at each genomic locus (Table 2). LP1.T3 integration at each site was confirmed 
by colony PCR using primers that amplify the 5' and 3' genomic regions flanking LP1 integrant 
(Appendix Table A13). Positive integrant colonies were sequence verified and cultured for two 
days in YPD to remove the pCAS plasmid. The LP1.T3.SiteX strains were saved in 15% glycerol 
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solution and stored at -80°C. The strains were streaked onto YPD to obtain single colonies for 
subsequent testing of synthetic gRNAs. 
 
Construction of CEN.LP strain 
The LP platform was built into S. cereivisiae strain CEN.PK2-1D by Michael Pyne. Full-
length LPX.TX constructs were generated by PCR using primers to introduce target sites to the 
LPX.A and LPX.Z recombinogenic regions. The LPX donor constructs were generated by PCR 
using primers to attach ~60 bp homology to the assigned genomic loci (Appendix Table A7). Donor 
constructs include: LP1.T8 with homology to site FgF20; (x2) LP2.T10 donors with homology to 
sites FgF18 and FgF24; (x3) LP3.T7 donors with homology to sites UserXII-1 and FgF7, FgF19; 
(x4) LP4.T9 donors with homology to sites FgF12, FgF16, FgF21, FgF22. The LP platform was 
constructed by integrating one or two LP donor constructs in successive co-transformations with 
the site-specific targeting gRNA(s) (Appendix Table A6) and linearized pCAS vector backbone. 
LPX integrations were confirmed by colony PCR using site-specific primers that amplify the 5' and 
3' genomic regions flanking LPX integrants (Appendix Table A13). The CEN.LP strain was 
sequence verified and cultured for 2 days in YPD to remove the pCAS plasmid. The strain was 
saved in 15% glycerol solution and stored at -80°C. 
 
Construction of CEN.LP.D  
In order to test the NCS variants, a dopamine production cassette was inserted into the 
CEN.LP strain to provide substrate for de novo synthesis of (S)-norcoclaurine (work done by 
Michael Pyne). The three-gene dopamine production cassette (PTDH3-CYP76AD1
W13L/F309L-
TTDH1;TTDH1;PCCW12-DODC-TADH1;PPGK1-ARO4
FBR-TPGK1 ) was developed and provided by Deloache 
et al. (2015). For genomic integration into the CEN.LP genome, the cassette was amplified from 
the pWCD2249 plasmid (Accession number KR232306.1) in two overlapping fragments along with 
flanking homology to the ARO4 locus in S. cerevisiae (Appendix Table A12). The four donor 
fragments were co-transformed with pCAS vector backbone and a gRNA targeting ARO4 
(Appendix Table A6). Overlapping fragments assembled in vivo and replaced the native ARO4 
sequence upon integration. Correct assembly and integration was confirmed by colony PCR using 
primers that amplify the 5' and 3' genomic regions adjacent to the integration (Appendix Table 
A13). The CEN.LP.D strain was sequence verified and cultured for two days in YPD to remove 
the pCAS plasmid. The strain was saved in 15% glycerol solution and stored at -80°C. 
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2.6. Colony PCR 
Individual colonies were suspended in 15 µl sterile water. Five µl was transferred into 30 µl 
20 mM NaOH and microwaved for two min. One µl was used as template for colony PCR using 
the Phire™ Plant Direct PCR Master Mix (Thermo Fisher Scientific ). Primers used for colony PCR 
are site-specific and anneal to genomic DNA adjacent to the integration site (Appendix Table A13 
& Table A14). Integration of donor DNA was verified by the size difference between amplicons 
generated for positive and negative integration events. 
 
2.7. Preliminary tests 
Synthetic gRNA efficacy 
Targeting specificity of gRNAs was determined by measuring the lethality of Cas9-induced 
DSBs generated by cells expressing cas9 and a targeting gRNA without repair template. We 
describe this relationship as the percent kill (% kill), where higher % kill is associated with lower 
CFU values of transformants plated on selective medium. Percent kill was measured by co-
transforming linear gRNAX constructs with linearized pCAS vector backbone harbouring cas9 into 
LP1.TX strains and comparing the CFU against the same strains co-transformed with pCAS 





 )) ×  100  
 
We also calculated the percent kill for each gRNAX construct co-expressed with cas9 in the 
CEN.PK2-1D background strain lacking an LP1.TX target site. 
 
Integration efficiency was measured by co-transforming linearized gRNAX and pCAS vector 
backbone with the LP1.gfp donor with full-length LP homology into the corresponding LP1.TX 
strains. Integration efficiency of the gfp donor was calculated for each gRNAX by genotyping 12 
colonies per transformation plate. 
 
Targeted integration efficiency into selected genomic loci 
Integration efficiency into LP1.T3 at each genomic locus was measured by co-transforming 
linearized gRNA3 and pCAS vector backbone with the LP1.gfp donor with full-length LP homology 
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into the corresponding LP1.T3.SiteX strain. After selecting for assembly of the pCAS plasmid, 
integration efficiency of the donor DNA into each genomic loci was calculated by genotyping 12 
colonies per transformation plate using the primers listed in Appendix Table A13.  
 
2.8. Integration into the LP platform 
Integration efficiency into each LP motif was measured by co-transforming linearized 
LPX.gRNA (400-800 ng) and pCAS (250 ng) vector backbone with LPX.gfp donor constructs  
(1-4 µg): LP1.gfp donor was co-transformed with gRNA8; LP2.gfp donor was co-transformed with 
gRNA10; LP3.gfp donor was co-transformed with gRNA7; and LP4.gfp donor was co-transformed 
with gRNA9. For testing the effect of homology length on transformation efficiency, we also co-
transformed LPX.gfp donor constructs harbouring full-length homology to each LPX construct. 
Integration efficiency was calculated by genotyping a minimum of 12 colonies per transformation 
using the LP primer sets listed in Appendix Table A14 to check for integration at each site within 
the LP motif. Strains harbouring gfp in each LP motif were sequence verified, saved in 15% 
glycerol solution and stored at -80°C. 
 
2.9. GFP expression analysis 
Fluorescence levels were measured for strains expressing GFP at different genomic loci 
and copy numbers by cultivating the LP1.gfp.SiteX or LPX.gfp strains overnight in SC with 2% 
glucose (w/v). Overnight cultures were then diluted 10× into fresh medium and incubated for an 
additional 4 h to obtain log phase cells. Fluorescence was measured from cell suspension using 
a microplate reader and normalized against OD600 for three biological replicates. Fluorescence 
was detected by the TECAN M200 plate reader using an excitation wavelength of 485 nm and an 
emission wavelength of 525 nm. Gain was adjusted for each sample. The background strain 
lacking GFP was used to correct for autofluorescence generated by cells and medium. 
 
2.10. NCS enzyme candidates 
The NCS enzyme library used in this study was previously curated by James Scriven by 
querying the PhytoMetaSyn transcriptome database (http://www.phytometasyn.net). NCS 
nucleotide sequences (Appendix Table A15) were codon-optimized for expression in  
S. cerevisiae. NCS open reading frames (ORFs) were synthesized by Gen9 and cloned into the 
pBOT(HIS) expression vector between the TEF1 promoter and the GFP fusion tag. The GFP tag 
was subsequently removed by restriction enzyme digestion with KasI (NEB). NCS amino acid 
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sequences (Appendix Table A16) were aligned by MUSCLE (Appendix Figure A1) and 
phylogenetic trees were generated using the neighbour-joining method in MEGA7.0 [79] with a 
bootstrap value of 1000. Sequence identities between NCS variants (Appendix Table A17) were 
scored using BLASTp [80] multiple sequence alignment software. 
 
NCS copy number integration into LP platform 
NCS variants were integrated into each LP motif of the CEN.LP.D strain using the LP 
platform integration strategy outlined in section 2.8. Transformants were screened by colony PCR 
using primer sets listed in Appendix Table A14 to check for NCS integration at each site within the 
targeted LP motif. Forty LP.NCS variant and copy number strains were sequence verified and 
saved in 15% glycerol solution and stored at -80°C. Strains were streaked out on YPD to obtain 
single colonies for activity assays. 
 
(S)-Norcoclaurine production assay 
Colonies were picked in triplicate and inoculated into 200 ml of YPS in 96-well two ml deep 
well plates. Cultures were incubated at 30°C with shaking at 200 rpm for 16 h. Overnight cultures 
were diluted to an OD600 of 0.3 into 1.8 ml of YPS. A 180 µl aliquot was transferred to a 96-well 
microtiter plate and incubated at 30°C in the Sunrise® absorbance microplate reader (Tecan) with 
shaking at 200 rpm. Cell density was measured using an OD600 at 20 min intervals for 48 h to 
monitor growth rate (Appendix Figure A2). The remaining 900 µl of culture was grown in a 96-well 
two ml deep well plate and incubated at 30°C with shaking at 200 rpm. After 96 h, the cultures 
were centrifuged at 4,000 rpm for 5 min. Culture supernatant was collected and suspended 1:1 in 
60% acetonitrile + 0.2% formic acid (final concentration 30% acetonitrile + 0.1% formic acid) for 
LC/MS analysis. 
 
LC/MS detection and quantification of dopamine and (S)-norcoclaurine. 
Production of dopamine and (S)-norcoclaurine was analyzed using the 1290 Infinity II LC 
system, (Agilent Technologies) with a Zorbax Eclipse Plus C18 50 × 4.6 mm column (Agilent 
Technologies). Solvent A (100% water, 0.1% formic acid) and solvent B (100% acetonitrile, 0.1% 
formic acid) were used in a gradient elution to separate metabolites. Samples were separated 
using a linear gradient: 0-5 min 98% A/ 2% B, 5-7 min 90% A/ 10% B, 7-7.1 min 15% A/ 85% B at 
a flow rate of 0.3 ml/min followed by a 3 min equilibration at 100% A at a flow rate of 0.4 ml/min 
[75]. Following liquid chromatography (LC) separation, eluent was then injected into a 6560 Ion 
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Mobility Q-TOF LC/MS, (Agilent Technologies). The system was operated in positive electrospray 
(ESI+) mode using the following parameters: capillary voltage 4000V; fragmentor voltage 400V; 
source temperature 325°C; nebulizer pressure 55 psig; gas flow 10 L/min. Dopamine and (S)-
norcoclaurine standards (Toronto Research Chemicals Inc.) were used to determine retention 
times and to generate calibration curves. For identification and quantification of dopamine (m/z 
154.086 [M+H]+; Rt 1.2 min) and (S)-norcoclaurine (m/z 272.121 [M+H]+; Rt 4.3 min), the extracted 
ion counts were normalized against an eight-point calibration curve ranging from 0.0078–2 mM 
(dopamine) and 0.078-10 µM ((S)-norcoclaurine) in two-fold increments. The LC/MS were 
analyzed using MassHunter quantitative analysis software (Agilent Technologies). 
3. RESULTS 
3.1. Landing Pad platform design and optimization 
 The LP platform was designed to accommodate marker-less, multi-copy gene integration 
into the S. cerevisiae genome in a single reaction. The platform uses a series of synthetic DNA 
blocks called ‘landing pads’ (LPX) (Figure 1A) inserted into the S. cerevisiae genome at different 
loci, to serve as modular anchors for CRISPR-mediated gene integration.  The LP platform was 
built by inserting four distinct LPX constructs in one, two, three, or four copies into the S. cerevisiae 
genome at various loci (Figure 1B). LPX  motifs were then used as modular target sites for CRISPR-
Cas9-mediated integration of genes in up to four copies in a single transformation. 
 
Landing pads consist of three components to accommodate the CRISPR/Cas9 genome 
editing system: i) a 20-nt gRNA target sequence (N20), ii) an 5'-CGG-3' PAM, and iii) two unique 
recombinogenic regions (LP.A/LP.Z) flanking the target site (Figure 1A). The process for CRISPR-
mediated gene integration into the LP platform is illustrated in Figure 2, and begins by co-
transforming a plasmid encoding cas9 and the appropriate gRNAX along with a gene cassette 
repair donor possessing LPX homology. We selected the CRISPR/Cas9 system designed by Ryan 
et al. (2014)  to deliver cas9 and gRNA from a single 2μ plasmid (pCAS). The gene cassette 
flanked by LP.A and LP.Z homology acts as template for HDR of the DSB through recombination 
with the LPX recombinogenic regions. Upon integration into an LPX, the gene cassette replaces 
the Cas9 target site, resulting in permanent and stable gene integration into the chromosome. 
 
To build the LP platform, we first designed the landing pad components in silico using an 
online sequence generator to create the synthetic landing pad recombinogenic regions and gRNA 
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target sequences. We randomly generated four blocks of DNA sequence (560 bp) with ~50% GC 
to comprise the four unique LPs. The recombinogenic blocks, designated LP1, LP2, LP3 and LP4 
were synthesized as gBlocks and then amplified in two halves to generate the LP.A and LP.Z 
recombinogenic regions (Appendix Table A3). We also generated a total of ten 20-nt DNAs with 
>40% GC to serve as gRNA target sequences immediately upstream of a PAM (5'-N20CGG-3'). 
Together, the target sequence and PAM make up the LP target sites, which were synthesized as 
custom oligos and used to assemble the full 583 bp LPX constructs. 
 
We performed a number of preliminary tests to optimize the operation and efficiency of our 
devised LP system. First, we evaluated all 10 synthetic gRNA target sequences by measuring 
Cas9 endonuclease activity and targeted integration efficiency. We then compared integration 
efficiency and gene expression levels at different genomic loci and selected those sites that were 
easily modified and showed similar levels of transcription. Results gleaned from these tests 
informed the construction of our LP platform. 
 
3.2. Characterization of synthetic gRNA candidates 
To select four functional gRNA/target pairs to use in the LP platform, we generated 20-nt 
strings of DNA using a random sequence generator (http://www.faculty.ucr.edu/ 
~mmaduro/random.htm) and selected those with >40% GC content. After including the PAM, the 
5'-N20CGG-3' target sites were queried against the Saccharomyces Genome Database (SGD) to 
eliminate those with potential off-target homology. A total of ten gRNA targeting sequences 
matching our criteria were selected for further evaluation (Table 1). To test the functionality of 
each synthetic gRNA in vivo, we first integrated LP1 constructs harbouring each of the ten gRNA 
target sites (LP1.TX) into S. cerevisiae CEN.PK2-1D at the FgF20 locus, yielding a total of ten 
strains (Figure 3A & 3B). The corresponding gRNAX expression cassettes containing the selected 
targeting sequences were then co-transformed with cas9 into the respective LP1.TX strain to 
evaluate site-specific Cas9 nuclease activity, as well as the associated efficiency of targeted 
integration of donor DNA (Figure 3C). 
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Table 1. Synthetic gRNAx candidates 
 
gRNAX targeting specificity 
To test the targeting specificity of the gRNAs, we exploited the lethal consequence of 
chromosomal DSBs created when Cas9 endonuclease is guided to a genomic target site by a 
functional gRNA. Without a repair template, successful delivery of Cas9 to the chromosomal target 
site results in cell death [39, 81] and is observed as a low CFU when compared to a transformation 
control. High % kill indicates that the gRNA successfully guides Cas9 to the genome, and induces 
a lethal DSB in the chromosome. Percent kill was measured by co-transforming linear gRNAX 
cassettes with a linearized pCAS plasmid backbone into LP1.TX strains and comparing the CFU 
against the same strains co-transformed with the pCAS backbone and a control (–)gRNA cassette 
(Figure 3C). Following a 16 h outgrowth recovery period, transformants were plated on medium 
selecting for assembly of the pCAS plasmid via gap repair between the gRNA cassette and the 
pCAS backbone. Percent kill was calculated for each gRNAX using the formula outlined in section 
2.7 and ranged from 77-100% (Figure 3D). An average kill efficiency >90% was observed for all 
gRNAX constructs targeting the LP1.TX site. Both gRNA10 and gRNA8 produced nearly 100% kill 
efficiency, closely followed by gRNA5, gRNA7, gRNA9, and gRNA1 (98% kill). 
 
To rule out possible off-target effects and ensure the % kill values reported above represent 
correct targeting between the synthetic gRNAX and LP1.TX landing pad, we also calculated the % 
kill of gRNAX and cas9 co-expressed in the wild-type strain lacking LP1.TX target site (Figure 3C). 
We suspected that if gRNAX showed off-target activity, % kill would be similar between the wild-
type and LP1.TX strains. The results show that % kill observed for gRNAs expressed in the parent 
strain were significantly less than those attained in the LP1.TX strains, suggesting highly specific 
targeting of gRNAs to the correct LP1.TX sites. However, potential off-target activity was observed 
for gRNA4 (12.2 ± 14.1%), gRNA5 (17.0 ± 25.0%) and gRNA6 (15.9 ± 13.9%) in the wild-type 
gRNA Targeting sequence %GC LP target site 
gRNA1 CTAGATAAGACGTGGCAGAT 45 CTAGATAAGACGTGGCAGATCGG 
gRNA2 CCACCGCTCAGTAGCGGCTT 65 CCACCGCTCAGTAGCGGCTTCGG 
gRNA3 GCCAGTCAGAACACTAGAGG 55 GCCAGTCAGAACACTAGAGGCGG 
gRNA4 ACGCCGTTTTTCACATCTGT 45 ACGCCGTTTTTCACATCTGTCGG 
gRNA5 GATACAACCCATCCGCGCTA 55 GATACAACCCATCCGCGCTACGG 
gRNA6 ACGTGTCATACGAGGTATAG 45 ACGTGTCATACGAGGTATAGCGG 
gRNA7 ATTGTACCCCAGCGGCGGCG 70 ATTGTACCCCAGCGGCGGCGCGG 
gRNA8 TAAGTCCGCGGATAACCATT 45 TAAGTCCGCGGATAACCATTCGG 
gRNA9 GTAGCCCAACAGGAGCACAT 55 GTAGCCCAACAGGAGCACATCGG 
gRNA10 TCCCCAATCGTGGAGTGAAG 55 TCCCCAATCGTGGAGTGAAGCGG 
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strain.  Still, the relatively low % kill and broad variation between replicates suggests these gRNAs 
are only partially complementary to off-target sites within the wild-type genome. The remaining 
gRNAs showed % kill values of <5% in the parent strain compared to >91% kill in LP1.TX strains, 
indicating that these gRNAs show high specificity to their intended LP1.TX target sites and are 







Figure 3. Targeting specificity of ten synthetic gRNAx candidates 
(A) Schematic overview of LP1.TX integration into S. cerevisiae. Ten LP1.TX strains were generated to 
evaluate performance of the synthetic gRNAs. Targeting sequences complementary to the 10 synthetic 
gRNA candidates were assembled into LP1.TX constructs and integrated separately into locus FgF20. wt: 
parent strain CEN.PK2-1D. (B) Genotyping of LP1.TX integration into FgF20. Lane 1: 100 bp ladder, lane 2: 
parent strain CEN.PK2-1D (–) control, lanes 3 – 12: LP1.TX integrations in the following order T1, T2, T3, 
T4, T5, T6, T7, T8, T9, T10. (C) Schematic overview of synthetic gRNA efficacy tests. i) Synthetic gRNA 
targeting specificity tests were performed by co-transforming pCAS vector backbone with each gRNAX into 
the complementary LP1.TX target strain to evaluate % kill. The % kill was also calculated for gRNAX 
expression in the parent strain lacking a LP1.TX construct. ii) Efficiency of gRNAX targeted integration was 
evaluated by co-transforming the pCAS backbone and gRNAX with a linear gfp cassette flanked by LP1 
homology into each LP1.TX strain. (D) Synthetic gRNA target specificity and efficiency tests. Comparison of 
the % kill for each synthetic gRNA co-expressed with Cas9 in wt (–) versus the LP1.TX strains (+). Percent 
kill was evaluated by comparing the number of transformants grown on medium selecting for gRNA 
expression against a (–)gRNA transformation control.  Error bars represent the mean ± s.d. of three 
separate assays. (E) Synthetic gRNA targeted integration efficiency.  Integration efficiency calculated for a 
1.5 kb gfp donor cassette with LP1 homology arms into LP1.TX strains using the appropriate gRNAX in 
combination with pCAS. Integration efficiency was determined by genotyping selected colonies. Error bars 
represent the mean ± s.d. of three separate assays. wt: parent strain CEN.PK2-1D. 
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Targeted integration efficiency associated with synthetic gRNAX candidates 
Considering that targeted gene integration is a critical component of the landing pad 
system, we set out to test whether the selected gRNAs facilitated efficient gene integration. To 
quantify the efficiency of integration into the ten LP1.TX strains, we co-transformed the linear 
gRNAX cassettes and pCAS backbone along with a 1.5 kb gfp expression cassette (PTDH3-gfp-
TCYC1) flanked by 280 bp homology arms complementary to the LP1 recombinogenic regions 
(Figure 3C). In this experiment, gfp donor DNA acted as the repair template for the CRISPR/Cas9-
induced DNA break at LP1.TX via homologous recombination with LP1 [28, 82].  After selecting 
for assembly of the pCAS plasmid, integration efficiency of the gfp donor was calculated for each 
gRNAX by genotyping 12 colonies per strain. Integration efficiencies observed for gfp at each 
LP1.TX site ranged from 58 – 92% (Figure 3E). The highest integration efficiencies were observed 
for gRNA9 (91.7 ± 4.2%) and gRNA10 (91.7 ± 4.2%), whereas gfp integration using gRNA2 was 
only 58.3 ± 18.1%. To eliminate the possibility that integration occurred in the absence of a Cas9-
induced DSB, we transformed the gfp repair template without gRNA and plated on medium 
selecting for the pCAS (–gRNA) plasmid.  Out of 72 colonies screened, only a single colony 
contained the gfp cassette integrated into LP1. Considering that native YHR-mediated integration 
occurred at very low frequency, the integration efficiency reported for each gRNAX is a direct result 
of the DSB induced by the CRISPR/Cas9 system. 
 
Based on the integration efficiency data, we selected gRNA7, gRNA8, gRNA9 and gRNA10 
to form the basis of the LP platform strain. All four gRNAs demonstrated near perfect targeting 
efficiency with high specificity to the LP1.TX target site, and offered among the highest targeted 
integration efficiencies (83-92%) of the ten synthetic gRNAs tested. 
 
3.3. Characterization of S. cerevisiae genomic loci for high level gene 
expression 
Selection of genomic loci for efficient integration and stable expression of genetic 
constructs is another critical component of the LP platform. To reveal a correlation between gene 
expression and gene dosage, it is important that the selected loci exhibit similar levels of 
transcription. In this context, we selected 15 loci (Table 2) based on previous work done by 
Flagfeldt et al. (2009) who measured gene expression levels at 20 different genomic loci using a 
LacZ reporter enzyme [61]. Since we were interested in the sites showing high gene expression, 
we excluded five sites showing low levels of expression in their study. Twelve of the sites chosen 
for this work contain solo long terminal repeats (LTRs), which are removed upon LP integration, 
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while the remaining three consist of an inactive URA3 locus, the PDC6 locus, and the intergenic 
region between housekeeping genes SPB1 and PBN1 [61]. We also selected the USERXII-1 site 
based on work done by Mikkelsen et al. (2012) to evaluate alongside the Flagfeldt (FgF) sites due 
its proven reliability within our laboratory. The USERXII-1 site is situated within an intergenic 
region on chromosome XII, and showed high gene expression levels when evaluated with a LacZ 
reporter enzyme [62]. We first re-evaluated the genomic loci from previous work to test the 
efficiency of CRISPR/Cas9-mediated integration and quantify gene expression at each site. To 
perform these tests, we integrated the LP1 construct harbouring target site 3 (LP1.T3) into all 16 
selected loci (Figure 4A), yielding 16 LP1.T3.SiteX strains for evaluation (Appendix Table A1). 
 
Table 2. Genomic loci (SiteX) candidates for characterization 
SiteX Description Chromosome Coordinates Deletion Region Ref 
FgF1 LTR I 21839-23155 22221-22575 [61] 
FgF5 LTR III 290999-292320 291360-291805 [61] 
FgF7 LTR V 248671-249726 249071-249383 [61] 
FgF8 LTR XII 319986-321371 320344-320770 [61] 
FgF11 LTR XI 528976-531074 529266-530388 [61] 
FgF12 LTR IX 425603-427250 426198-426544 [61] 
FgF14 LTR XIII 480888-482601 481480-481859 [61] 
FgF16 LTR XIV 726641-728332 727268-727659 [61] 
FgF18 LTR XV 664036-665684 664793-665233 [61] 
FgF19 LTR XV 968527-970120 969238-969467 [61] 
FgF20 LTR XVI 775916-777558 776567-776868 [61] 
FgF21 LTR XVI 880684-882562 881333-881964 [61] 
FgF22 URA3 V 115710-117433 116214-116932 [61] 
FgF23 Intergenic region III 33108-34547 34005-34072 [61] 
FgF24 PDC6 XII 651035-653434 651504-652891 [61] 
UserXII-1 Intergenic region XII 4105-4676 4165-4616 [62] 
 
 
Targeted integration efficiency into candidate genomic loci (SiteX) 
Integration efficiency at each genomic locus containing the LP1.T3 landing pad was 
measured by co-transforming the LP1-gfp donor cassette with linearized gRNA3 and pCAS 
plasmid into each LP1.T3.SiteX strain (Figure 4B). After selecting for assembly of the pCAS 
plasmid, integration efficiency of the gfp donor was calculated for each site by genotyping 12 
colonies per strain. Efficiency of targeted gfp integration into LP1.T3 varied from 64 – 92% 
between the 16 genomic loci (Figure 4C). An average integration efficiency of >80% was observed 
for 10 of the 16 loci (FgF7, 8, 12, 14, 16, 18, 20, 21, 24, UserXII-1), whereas sites FgF1, 5, 11, 
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19, 22 and 23 showed average integration efficiencies of >60%. For at least one experimental 
replicate, targeted integration reached 100% efficiency for sites FgF7, FgF16, FgF18 and FgF24. 
Since the CRISPR machinery and donor DNA remained constant between strains, it is possible 
that the rate of integration was influenced by the structural dynamics of chromatin at each locus, 
which would affect the ability of the Cas9-gRNA complex to target and bind DNA [50]. 
 
Analysis of gene expression at genomic loci 
Gene expression was assayed from each of the 16 candidate sites by measuring 
fluorescence levels resulting from integration of gfp at each locus. The gfp cassette expresses the 
GFPS65T mutant protein [83] controlled by regulatory elements PTDH3 and TCYC1 to achieve high 
levels of expression [17, 20]. Likewise, the GFPS65T mutant protein (herein referred to as GFP) 
has improved fluorescence qualities that enables real-time quantification of gene expression in  
S. cerevisiae [84]. Fluorescence values were then normalized against OD600 and corrected for 
autofluorescence detected from the background strain and medium. The results showed a nearly 
seven-fold difference in fluorescence between strains expressing gfp from the 16 genomic sites 
(Figure 4D). Integration of gfp at sites FgF1 and FgF11 resulted in the highest levels of 
fluorescence, generating roughly 1.7-fold higher fluorescence than the average of all sites, 
whereas FgF5 showed the lowest level of fluorescence, approximately 4-fold lower than the 
average. These sites were not selected for use in the LP platform due to the significant deviation 
in gene expression compared to all other sites. The 13 remaining genomic loci exhibited similar 
expression profiles, showing fluorescence values within ± 1.2x from the mean fluorescence and 





Figure 4. Evaluation of selected genomic loci in S. cerevisiae 
(A) Construction of LP1.T3 strains for assaying integration efficiency and gene expression at each 
genomic locus. Sixteen LP1.T3.SiteX constructs were generated by assembling and integrating LP1.T3 
with ~500bp homology arms to each site. (B) Schematic overview of integration efficiency tests. 
Integration efficiency was assayed by integrating an LP1.gfp donor into the selected genomic sites using 
gRNA3 and pCAS. (C) Integration efficiency data at the genomic loci. Integration efficiency was 
determined by genotyping 12 colonies from each targeted genomic locus. Error bars represent the mean 
± s.d. of three separate assays. (D) Gene expression levels at candidate genomic loci. Fluorescence 
intensity was measured for strains carrying gfp integrated into 16 different genomic loci. Fluorescence 
measurements were normalized against OD600 and corrected against autofluorescence of the (–) wt 
control and medium.  Error bars represent the mean ± s.d. of three biological replicates. Hatched grey 




3.4. Building a Landing Pad platform in S. cerevisiae 
Overview of the LP platform 
The LP platform was built into the quadruple auxotrophic S. cerevisiae strain CEN.PK2-1D 
to allow more versatility for downstream applications (work done by Michael Pyne). The 
composition of the final LP platform strain is illustrated in Figure 5A and includes four LP motifs: 
LP1, LP2, LP3 and LP4 that were integrated into the S. cerevisiae genome at different copy 
numbers reflected by their number designation (Table 3). Each of the four landing pads was 
assigned a single gRNAX/target site: LP1 contains the gRNA8 target site (LP1.T8), LP2 contains 
the gRNA10 target site (LP2.T10), LP3 contains the gRNA1 target site (LP3.T1) and LP4 contains 
the gRNA9 target site (LP4.T9). The landing pads were then inserted into CEN.PK2-1D at the 
genomic loci assigned to each LP motif by integrating one or two constructs at a time using the 
CRISPR/Cas9 system. Previous reports have suggested that introducing multiple DSBs to a single 
chromosome can cause genome instability and decrease integration efficiency and cell viability 
[7]. Hence, to avoid an unnecessary burden on the cell, identical landing pads were integrated 
into sites on separate chromosomes. LP1 was integrated at FgF20, LP2 was integrated at FgF18 
and FgF24, LP3 was integrated at UserXII-1, FgF7 and FgF19 and LP4 was integrated at FgF12, 
FgF16, FgF21 and FgF22. LP integrations were screened by colony PCR (Figure 5B) and 
sequence verified before the system was evaluated. 
 




LP integration loci Copy number 
integration 
Multiplex PCR 
 amplicon (bp) 
Site Chr 










FgF7 V 800 





FgF16 XIV 796 
FgF21 XVI 954 
FgF22 V 1110 
 
After all four LP motifs had been inserted into their assigned genomic loci, we assessed 
the targeting specificity of the gRNAX constructs selected for the LP platform to ensure that optimal 
targeting specificity was maintained.  The LP platform strain (CEN.LP) was transformed with pCAS 
plasmid harbouring one of the four gRNAX constructs assigned to LP1, LP2, LP3 and LP4 motifs 
(henceforth referred to as LPX.gRNA). Targeting specificity is expressed as the % kill and was 
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determined by comparing the transformation efficiencies of each LPXgRNA to the transformation 
efficiency of the (–)gRNA pCAS control plasmid. All four LPX.gRNA constructs displayed high % 
kill values of >95% (Figure 5C), demonstrating that high targeting efficiencies of the selected 
LPX.gRNAs were preserved within the LP platform. Next we set out to evaluate the usefulness of 
the system by i) measuring the efficiency of CRISPR/Cas9-mediated integration into LP1, LP2, 
LP3 and LP4 using gfp donor DNA, and ii) comparing the expression level of gfp expressed from 
the chromosome in 1-copy (LP1), 2-copies (LP2), 3-copies (LP3) and 4-copies (LP4). The purpose 
of these tests was to ensure that the LP platform supports efficient multi-copy gene integration 
and reliable titration of gene copy number, with the intention that it be used as a tool to help 




Figure 5. Overview of the LP platform in S. cerevisiae 
(A) Left panel: Each landing pad was assigned a gRNAX target site and the resulting constructs were 
integrated into a single strain of S. cerevisiae at the selected genomic loci. Right panel: The LP platform 
strain in S. cerevisiae (CEN.LP) consists of four different landing pad motifs inserted into the genome at 
incremental frequency: LP1 = 1 locus, LP2 = 2 loci, LP3 = 3 loci, LP4 = 4 loci. Identical LPs were inserted 
on different chromosomes. (B) Genotyping of the final CEN.LP strain. LP integrations were screened using 
an LP-specific internal primer and a site-specific external primer. The parent strain CEN.PK2-1D (–) and the 
platform strain CEN.LP (+) were used as template. (C) Targeting specificity of selected LP.gRNAs into the 
LP platform.  LPX.gRNA targeting specificity tests were performed by co-transforming pCAS vector backbone 





Overview of the LP platform integration strategy 
Titration of gene copy number is performed in parallel using the devised LP platform 
integration strategy (Figure 6). The process begins by assembling four donor DNA constructs by 
PCR-amplification of a gene cassette using primers to attach 60 bp homology arms 
complementary to LP1, LP2, LP3 and LP4. The resulting donors are then co-transformed into 
CEN.LP in parallel with linear pCAS backbone and the LPX.gRNA to target the appropriate landing 
pad: gRNA8 targets LP1, gRNA10 targets LP2, gRNA1 targets LP3, and gRNA9 targets LP4. 
Cells are plated on media selecting for expression of the pCAS plasmid, and the resulting 
transformants are screened by PCR to check for integration into each LP motif. Using the platform 
in its most basic form generates four S. cerevisiae strains harbouring 1-4 copies of any gene-of-
interest in less than one week. The strains can then be tested in parallel to evaluate the effects of 
gene dosage on protein expression and activity.  
 
 
Figure 6. LP platform integration strategy 
Donor DNA constructs are prepared by amplifying any gene of interest using primers to attach 60 bp homology 
arms. LPX.donors are co-transformed independently with pCAS plasmid backbone and the respective 
LPX.gRNA into the LP platform strain. Transformants are plated on media selecting for assembly of the pCAS 
plasmid. Integration of donor DNA occurs upon homology-directed repair of DSBs generated by Cas9 nuclease 
activity at the targeted LP. 
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3.5. Targeted integration efficiency into designated LP integration sites 
Prior to applying our CEN.LP platform to a metabolic pathway, we first applied our devised 
landing pad integration strategy (Figure 6) using gfp as donor DNA and reporter gene. The gfp 
expression cassette (PTDH3-gfp-TCYC1) was integrated into the chromosome in 1-4 copies by 
targeting each of the LP motifs in four separate parallel transformations. Targeted integration into 
each LP motif was verified by colony PCR using locus-specific primer pairs for all loci within the 
LP motif. To accommodate multiplex PCR, primer pairs were originally designed so that 
amplification of each LP locus within the motif generated a different sized product in a single 
reaction (Table 3). This strategy was abandoned, however, as it often resulted in false negatives 
due to non-specific amplification. Instead, we used the same primer pairs to screen each LP site 
individually (Figure 7A). To evaluate the LP platform, we screened 12 colonies for each LP 
integration motif and counted the number of colonies with complete integration events. Overall, 
the rate of integration decreased as the number of targeted LPs increased (Figure 7B). Single-
copy integrations into LP1 showed the highest efficiency of 97% compared to 81% integration into 
LP2, 53% integration into LP3, and 39% integration into LP4. Unexpectedly, targeting multi-copy 
LP2, LP3, or LP4 motifs frequently yielded partial integrant colonies in which at least one of the 
targeted LPs did not contain donor DNA. Efforts to increase the efficiency of the LP system and 








Figure 7. Evaluation of the LP platform. 
(A) Genotyping of gfp copy number integrations into the LP platform. Lane 1: 1KB ladder; lanes 2-3: LP1.gfp 
integration; lanes 4-7: LP2.gfp integration; lanes 8-13: LP3.gfp integration; lanes 14-21: LP4.gfp integration. 
Successful integration of gfp at each locus (+) is shown alongside the LP platform strain (–). (B) Integration 
efficiency into the LP motifs. A gfp expression cassette flanked by LP homology arms was used as donor and co-
transformed with the pCAS LPX.gRNA expression vector into the LP platform strain. Transformation cultures were 
plated on selective medium and grown for two days. Integration efficiency was determined by genotyping 12 
selected colonies for integration into each LP motif. Error bars represent the mean ± s.d. of three separate assays. 
(C) Integration efficiency into LP motifs after an additional two-day incubation in selective liquid medium. 
Recovered transformation cultures were transferred into rich medium containing G418 selection and incubated for 
two days before plating on selective medium. Integration efficiency was determined by genotyping 12 selected 
colonies for integration into each LP motif. Error bars represent the mean ± s.d. of three separate assays. 
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While integration into LP1 was highly efficient, efficiency gradually declined as the number 
of targeted LP integration sites increased. To optimize multi-copy gene integration using the LP 
platform, we performed a series of tests to uncover the rate-limiting component of our CRISPR 
integration system. While many variables can contribute to the success of CRISPR/Cas9-
mediated gene integration, the availability of the gRNA, donor DNA and the Cas9 nuclease are 
the most influential and so we focused our efforts on these three components. 
 
First, we investigated whether the efficiency of multi-loci integration events was limited by 
availability of the gRNA or donor DNA during transformation. For all previous assays, the gRNA 
expression cassettes were introduced as linearized fragments with flanking homology to the pCAS 
vector backbone harbouring cas9 and the G418 selection marker. Assembly of these components 
is critical for: i) survival of transformants on selective medium, and ii) expression of gRNA and 
cas9 nuclease. Since the transformation efficiency of the integration samples (+donor, +gRNA, 
+cas9) was consistently lower than the (–)gRNA transformation control (–donor, –gRNA, +cas9), 
we examined whether increasing the amount of the gRNA insert used for the assay would improve 
the rate of in vivo assembly of the pCAS vector and/or increase the number of transformants 
containing full integration of donor DNA. However, titrating the amount of gRNA from 0.4 to 1 μg 
did not yield significant improvements in either the transformation efficiency or the rate of full 
integration of donor DNA into the multi-copy LP motifs (data not shown). One possible explanation 
for this could be that the amount of donor DNA introduced in the previous assays was insufficient 
or disproportionate to the amount required to repair multiple DSBs generated upon targeting the 
LP2, LP3 and LP4 motifs. Any gains in the transformation efficiency or integration efficiency would 
be lost if the concentration of donor DNA was too low to repair all DSBs with high efficiency. To 
account for this, we increased the amount of donor DNA from 1 to 4 μg to accommodate repair of 
each additional DSB. Considering that 1 μg of donor DNA gave 97% efficiency for single-copy 
integrations, we reasoned that titrating the amount of donor DNA by 1 μg/LP target site may 
improve integration into LP2, LP3 and LP4 motifs. To further facilitate homologous recombination 
between the LP sites and donor DNA, we also increased the donor homology arms from 60bp to 
280 bp as recommended by previous reports [54]. Implementation of these strategies, both 
independently and in combination, was also not effective for increasing the efficiency of multi-copy 
integration (data not shown). Taken together, these results indicate that neither the gRNA 
concentration, donor concentration, or homology length limit efficient multi-copy integration into 
the LP platform. 
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After establishing that multi-copy gene integration could not be improved by increasing the 
gRNA or donor concentration or increasing the donor homology length, we investigated whether 
our system was limited by activity of the gRNA targeting sequence and Cas9 nuclease. Evidence 
for this hypothesis was that partial integration of donor DNA continued to occur with the same 
frequency regardless of the gRNA or donor concentrations supplemented in the reaction. 
Furthermore, sequencing of LP3 and LP4 loci from partial integrant colonies revealed unmodified 
LP target sites in all cases where integration did not occur, indicating that a Cas9-mediated DSB 
had not been introduced to these sites. Since previous assays have already addressed the 
performance of the LPX.gRNAs and the integration efficiency at selected loci, other explanations 
for partial integration events include: i) the occurrence of a random mutation in the gRNA targeting 
sequence or cas9 coding sequence that abolishes CRISPR/Cas9 activity, or ii) expression and/or 
activity of the Cas9-gRNA complex is too low to generate multiple DSBs with high efficiency. To 
check whether gRNA or cas9 mutations were responsible for partial integration events, the pCAS 
plasmid was prepped from three partial integrant colonies per LP motif and sequenced. None of 
the pCAS plasmids extracted from these partial integrant colonies contained mutations within the 
gRNA expression cassette or the cas9 coding sequence, suggesting that poor performance of the 
Cas9-gRNA complex is likely a result of its abundance and activity level within the cell. 
 
Improving the activity and abundance of the Cas9-gRNA complex would require a complete 
overhaul of the CRISPRm expression and delivery system adopted for this work [53], including 
swapping of the cas9 or gRNA promoters to facilitate higher levels of expression, testing improved 
cas9 variants, and switching to an ultra-high copy plasmid. While these modifications could be 
beneficial for our system, we first opted to test whether multi-copy integration into the LP platform 
could be improved without converting to an entirely new CRISPR/Cas9 expression strategy. To 
this end, we investigated whether incubating the transformation culture in liquid selection media 
would improve integration efficiency, as has been suggested [21, 52], by allowing more time for 
the Cas9-gRNA complex to generate DSBs at each of the targeted LP integration sites. Following 
co-transformation of pre-cloned LPX.pCAS plasmids and LPX.donor DNA into the LP platform, 
transformation cultures were first recovered overnight in non-selective medium and then 
transferred into fresh liquid medium containing G418 selection. These cultures were then 
incubated for two days in liquid selection medium to pre-select for expression of the pCAS plasmid 
before plating. Twelve colonies were then screened for complete integration of the LPX.gfp donor 
into each of the LP motifs.  This additional two-day growth period in liquid selection resulted in 
nearly 100% integration into all LP motifs (Figure 7C). Integration into LP3 and LP4 showed 
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remarkable improvement, achieving efficiencies of 94% for LP3 and 97% for LP4 copy number 
integrations. Integration efficiencies of LP1 and LP2 also improved, with LP2 reaching 97% 
efficiency for two-copy integration and LP1 achieving 100% efficiency for all experimental 
replicates. These results show that multi-copy integration efficiencies improve by growing cells in 
liquid selection prior to plating, which prolongs expression of the pCAS plasmid. The extended 
selection pressure allows more opportunity for CRISPR/Cas9 machinery to induce DSBs over 
multiple generations. This exposure likely enriches the culture with positive integration events by 
selecting for cells able to repair newly generated DSBs via chromosomal repair using the donor 
DNA that had previously integrated into the motif as template. 
 
3.6. Titrating gene expression using the Landing Pad platform  
After optimizing multi-loci gene integration into the LP platform to nearly 100% efficiency, 
next we wanted to establish whether the platform accommodates titration of gene expression by 
measuring fluorescence from strains expressing gfp from each LP copy number motif. Since gfp 
mRNA is directly proportional to the level of GFP fluorescence [85], fluorescence intensity could 
be used as a proxy to determine whether gene expression is proportional to copy number using 
the LP platform. As expected, fluorescence intensity of the four LP-GFP strains correlated with 
gene dosage, as higher levels of fluorescence were observed in strains carrying more copies of 
gfp (Figure 8A). A roughly 50% increase in fluorescence was observed for each additional copy 
of gfp. This result illustrates that differences in gene expression between LP motifs is modulated 
by gene copy number, as expression between LP sites is comparable (Figure 4C). To investigate 
whether multi-copy gfp expression levels are equivalent to the sum of expression levels from 
single-copy integrations at each locus, we summed fluorescence values obtained from single-
copy gfp integrations (Figure 8B). Overall, the fluorescence generated by the sum of individual LP 
integrants mirrored the trend observed for strains harbouring multi-copy gfp integrations, though 
with slightly elevated fluorescence levels. Taken together, these results demonstrate that the 




Figure 8. GFP expression analysis 
(A) Fluorescence of LP platform strains expressing 1-4 copies of gfp. Fluorescence measurements were 
normalized against OD600 and corrected against the mean fluorescence of the wt (–) control.  Error bars 
represent the mean ± s.d. of three biological replicates. (B) Combined fluorescence of single-copy gfp 
integrations at each LP motif locus. Fluorescence measurements were normalized against OD600 and 
corrected against the mean fluorescence of the wt (–) control.  
 
3.7. Application of the Landing Pad platform 
(S)-Norcoclaurine production in S. cerevisiae 
Having established multi-copy integration of gfp using the landing pad platform, we next 
sought to apply our methodology to troubleshoot a key metabolic pathway bottleneck. In this 
regard, we targeted production of (S)-norcoclaurine, the central precursor to all BIAs [86].  
(S)-Norcoclaurine is formed by the condensation of the L-tyrosine derivatives 4-
hydroxyphenylacetaldehyde (4-HPAA) and dopamine, and is catalyzed by the enzyme 
norcoclaurine synthase (NCS) (Figure 9A). NCS catalyzes the first committed step in BIA 
biosynthesis and embodies one of the least efficient enzymes in the BIA biosynthetic network [64]. 
Conversion to (S)-norcoclaurine is limited by intracellular availability of 4-HPAA and dopamine 
substrates [75] and by the low catalytic efficiency of NCS [74], which reportedly only converts 
0.25% of dopamine to (S)-norcoclaurine [75]. To increase titers of (S)-norcoclaurine in S. 
cerevisiae, we focused on improving conversion efficiency of the NCS-catalyzed reaction. Using 
the LP platform, we sought to: 1) identify NCS variants showing improved enzymatic properties, 
and 2) test whether increasing NCS gene copy number produces higher titers of (S)-norcoclaurine 




Figure 9. De novo synthesis of (S)-norcoclaurine in engineered S. cerevisiae strains 
(A) De novo synthesis of (S)-norcoclaurine in S. cerevisiae towards the production of high-value BIAs. 
Mutant variation of ARO4 is shown in grey text Aro4FBR (ARO4 feedback resistant mutant), to increase 
production of tyrosine heterologous enzymes are shown in coloured text. Blue text indicates the enzymes 
involved in the synthesis of dopamine: CYP76AD1, tyrosine hydroxylase; DODC, DOPA decarboxylase 
for the conversion of tyrosine to dopamine via the chemical intermediate L-DOPA. Pink text indicates the 
enzyme involved in the synthesis of (S)-norcoclaurine: NCS, norcoclaurine synthase catalyzes the Pictet-
Spengler condensation of dopamine and 4-HPAA (4-hydroxyphenylacetaldehyde to generate (S)-
norcoclaurine. Examples of high-value downstream BIA products are shown in the grey box. Dash errors 
indicate multiple enzymatic steps (B) Strain construction process towards the synthesis of (S)-
norcoclaurine. Coloured budding yeast represent different strains that were built in this study and 




Engineering the CEN.LP strain to produce dopamine  
(S)-Norcoclaurine is formed through a Pictet-Spengler condensation between the 
substrates 4-HPAA and dopamine. In S. cerevisiae, 4-HPAA is formed endogenously from 4-
hydroxyphenylpyruvate (4-HPP), an intermediate in tyrosine biosynthesis [64], whereas synthesis 
of dopamine is dependent on introduction of heterologous enzymes into the cell (Figure 9A). 
Formation of dopamine from tyrosine is a two-step process involving hydroxylation and 
decarboxylation reactions that can occur in either order, though in yeast preference is given to the 
hydroxylation-first pathway, yielding the intermediate L-DOPA [64]. To impart dopamine 
biosynthetic capabilities to our landing pad strain and provide a background for norcoclaurine 
biosynthesis, we introduced a dopamine production cassette built by Deloache et al. (2015) [75] 
(Figure 9B). The cassette consists of three genes encoding a cytochrome P450 tyrosine 
hydroxylase from Beta vulgaris (CYP76AD1), a DOPA decarboxylase from Pseudomonas putida 
(DODC), and a feedback resistant mutant of yeast Aro4p (Aro4FBR) to increase intracellular 
accumulation of tyrosine [75]. The dopamine expression cassette was amplified from pWCD2249 
(Accession number KR232306.1) [75] in three overlapping fragments and integrated into the 
ARO4 locus of CEN.LP, thus replacing the native ARO4 gene with the ARO4FBR feedback resistant 
mutant. We then compared our dopamine-producing CEN.LP strain (CEN.LP.D) with yWCD745 
(accession number KR232306), the dopamine production strain built by Deloache et al. (2015) 
[75]. After 48h growth in SC medium containing 4% glucose, millimolar concentrations of 
dopamine (Figure 10A) were detected from the supernatant for both strains with strain yWCD745 
producing ~2.6x more dopamine than CEN.LP.D (Figure 10B). The difference in production 
observed between these two strains is likely an effect of the parent strains and integration loci 
chosen to introduce the heterologous genes. In their work, Deloache et al. used S. cerevisiae 
strain BY4741, derived from the S288c background, to integrate the dopamine cassette into the 
URA3 locus, which differs from our CEN.PK host background. Differences within the shikimate 
pathway, which is affiliated with aromatic amino acid biosynthesis have been observed in CEN.PK 
and S288c backgrounds [87], and so the availability of tyrosine and other key intermediates may 
vary between these two strains. Likewise, the dopamine production cassette was expressed from 
different loci in the two strains, therefore transcriptional levels of the dopamine-producing enzymes 
may be disproportionate as well. While the cellular environment in the S288c background seems 
more favourable for dopamine production compared to CEN.PK, the amount of dopamine 





Figure 10. Analysis of dopamine production in CEN.LP platform strain 
(A) LC/MS chromatogram of 1 mM dopamine standard (B) LC-MS analysis of dopamine in the 
supernatant of strain CEN.LP.D containing a dopamine production pathway (CYP76AD1; DODC; 




Compiling an NCS variant library 
The selected NCS candidates were part of a library of enzymes previously identified and 
obtained within our laboratory by querying the PhytoMetaSyn Project databases [88]. The 
collection includes 10 NCS orthologs from the plant families Papaveraceae, Ranunculaceae, 
Berberidaceae, and Menispermaceae (Table 4). Half of the NCS candidates have been expressed 
in yeast, including PsNCS1 [75] and PsNCS3 [74, 75]  from Papaver somniferum, NdNCS 
(Nandina domestica) [74] , TcNCS (Tinospora cordifolia) [75], and TfNCS (Thalictrum flavum)  [74, 
75]. To our knowledge the remaining NCS candidates have not been tested for activity in yeast 
and include AmNCS (Argenome mexicana), EcNCS (Eschscholzia californica), PsNCS2 (P. 
somniferum), ScNCS (Sanguinaria canadensis), and SdNCS (Stylophorum diphyllum). BLASTp 
analysis revealed the NCS candidates share 35-91% sequence identity (Appendix Table A17). 
Multiple sequence alignment and phylogenetic analyses (Figure 11A) showed AmNCS from the 
Papaveraceae family is the most distantly related ortholog, sharing between 35-47% sequence 
identity with the other variants. ScNCS and NdNCS (Nandina domestica) share 91% sequence 
identity despite belonging to different families. Likewise, SdNCS from Papaveraceae and TfNCS 




Screening NCS variants using the LP platform 
To enhance enzyme expression levels, the NCS sequences were codon optimized for 
expression in yeast and cloned into the pBOT-HIS vector system [10] between the PTEF1 and TPGI1 
regulatory elements. Using the integration strategy illustrated in Figure 6, 1-4 copies of each NCS 
variant were introduced into S. cerevisiae by co-transforming the LPX-NCS donors with pCAS and 
the associated LP.gRNAX into the CEN.LP.D strain. Transformants were plated on selective 
medium and screened for complete integration into each LP motif. The assay produced a total of 
40 NCS strains representing each variant integrated into S. cerevisiae genome in 1-4 copies. The 
resulting NCS variant and copy number library was assayed for de novo synthesis of (S)-
norcoclaurine. Since racemic norcoclaurine has been known to form spontaneously [65], the 
background strain lacking NCS was included to determine the rate of spontaneous production. 
After 96h cultivation in rich medium and 4% sucrose (w/v), LC/MS was used to measure the 
concentration of (S)-norcoclaurine in culture supernatants (Figure 11B), as nearly all (S)-
norcoclaurine synthesized by S. cerevisiae is secreted by the cell [75]. In the absence of an NCS 
enzyme, the CEN.LP.D strain did not produce detectable levels of norcoclaurine, suggesting that 
all norcoclaurine detected in cultures containing an NCS was produced enzymatically. 
Furthermore, enzymatic condensation of 4-HPAA and dopamine is enantioselective, therefore 
norcoclaurine produced by strains expressing NCS is expected to represent (S)-norcoclaurine 
[89]. 
 
Of the ten NCS variants, six produced detectable levels of (S)-norcoclaurine (EcNCS, 
NdNCS, PsNCS3, ScNCS, SdNCS and TfNCS) (Figure 11C). The best producers of (S)-
norcoclaurine were strains containing ScNCS and NdNCS, which yielded 60 μg L-l and 51 μg L-l 
respectively, for single-copy integrations. Generally, increasing NCS copy number improved the 
production of (S)-norcoclaurine in strains harbouring an active NCS variant, though the degree of 
improvement varied between the NCS candidates and between each additional gene copy.  The 
most pronounced improvements were observed for the top performing candidates. For example, 
four copies of ScNCS and NdNCS produced a greater than two-fold increase in (S)-norcoclaurine 







Figure 11. (S)-Norcoclaurine production from LP.NCSX strains 
(A) Predicted evolutionary relationships among NCS candidates selected from the PhytoMetaSyn database. 
Candidates represent NCS variants from ten different plant species across four plant families: Papaveraceae, 
Ranunculaceae, Berberidaceae and Menispermaceae. NCS amino acid sequences were aligned by MUSCLE. The 
phylogenetic tree was generated by MEGA7 using the Neighbor-Joining method with a bootstrap value of 1000. 
Confidence values were generated for each branch (indicated in grey). Active NCS variants are shown in red, 
inactive NCS variants are shown in black (B) LC/MS chromatogram of 10µM (S)-norcoclaurine standard (C) LC/MS 
analysis of (S)-norcoclaurine in the supernatant of cultures expressing an NCS variant in 1 – 4 copies. Error bars 
represent the mean ± s.d. of three biological replicates.  
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Table 4. NCS candidates screened in this study 
ID Species Family 
(S)-norcoclaurine 




AmNCS Argenome mexicana Papaveraceae – This study  
EcNCS Eschscholzia californica Papaveraceae 8.7 This study  
PsNCS1 Papaver somniferum Papaveraceae 
` This study  
– [75]  AKH61501.1 
PsNCS2 Papaver somniferum Papaveraceae – This study  
PsNCS3 Papaver somniferum Papaveraceae 
104.6 [75]  
– [74]  KP262411 
34.2 This study  
ScNCS Sanguinaria canadensis Papaveraceae 130.3 This study  
SdNCS Stylophorum diphyllum Papaveraceae 
– [74]  
33.8 This study  
NdNCS Nandina domestica Berberidaceae 
– [74]  
129.0 This study  
TcNCS Tinospora cordifolia Menispermaceae 
N/A [75] AKH61504.1 
– This study  
TfNCS Thalictrum flavum Ranunculaceae 
N/A [74]  
N/A [75]  
46.6 This study  
 
 
The LP platform enabled the simultaneous construction of 40 strains of S. cerevisiae 
expressing 10 different NCS variants from the genome in 1-4 copies. The LP platform facilitated 
the identification of two NCS candidates, ScNCS and NdNCS, producing superior (S)-
norcoclaurine titers. Moreover, increasing gene dosage of ScNCS and NdNCS from one to four 
copies using the LP platform resulted in twice as much (S)-norcoclaurine produced. These results 
showcase the utility of the LP platform as a system to efficiently screen, test and modulate the 
activity levels of different enzymes variants to help improve flux towards desired products in 




The LP platform was developed to accelerate efforts in yeast metabolic engineering 
towards the synthesis of high-value products. Engineering yeast to maximize production of novel 
compounds requires extensive pathway troubleshooting and optimization. Common genetic 
optimization strategies used to enhance flux through a target metabolic pathway include screening 
enzyme variants for improved activity [9, 65, 74, 75, 90], or tuning gene expression by testing 
different regulatory elements [67] and titrating gene dosage [21, 25, 90-92]. However, integrating 
new pathway modifications into the yeast genome remains a laborious process, and often 
necessitates many cycles through the design-build-test pipeline. There is a continual need to 
advance the pathway optimization process in order to reduce the time it takes to build superior 
yeast strains. The LP platform (Figure 5A) addresses this problem by providing a simple and 
efficient CRISPR/Cas9-based strategy for marker-less, multi-copy gene integration in  
S. cerevisiae, and was designed to facilitate enzyme library screens and test whether modulating 
gene copy number improves enzyme activity. 
 
4.1. Benchmarking the Landing Pad platform 
The majority of multiplexed CRISPR/Cas9 engineering strategies established in  
S. cerevisiae have focused on developing new methods for chromosomal integration of large 
multi-gene pathways [21, 53-55] and for simultaneous replacement of multiple native genes [28, 
52, 56]. The work described here intends to expand the toolbox for multiplexed engineering in 
yeast by providing a well-characterized and reliable platform to facilitate multi-copy gene 
integrations for titrating gene dosage. The novelty of the LP platform is based on the following 
features: 1) synthetic target sequences and recombinogenic regions that are entirely unique within 
the yeast genome, 2) a single gRNA and donor DNA for integrating multiple copies of a gene in a 
single assay, and 3) systematic titration of gene copy number to easily test the effects of gene 
dosage. Unlike other multiplexed CRISPR/Cas9 engineering strategies, the LP platform is 
composed of synthetic parts. This allowed us to customize and scrutinize all of the components 
required to build the platform, including Cas9 targeting sequences (Figure 3) and recombinogenic 
regions (Appendix Table A3), which were then inserted into selected integration sites (Figure 4). 
Introducing artificial CRISPR/Cas9 ‘landing pads’ into the genome also allowed us to overcome a 
few limitations that can arise when targeting the same regions in the wild-type genome. For 
instance, customization allowed us to design a platform that supports multi-gene integration using 
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a single gRNA and donor DNA for gene integration into one, two, three, or four loci (Figure 6, 
Figure 7), whereas targeted integration at the same sites in the wild-type genome would require a 
gRNA and donor DNA for each individual target site. Indeed, it is possible to target multiple loci in 
the native genome using a single gRNA and donor DNA. By targeting the delta (δ) sequences that 
are distributed across the yeast genome, Shi et al. (2016) were able to integrate multiple copies 
of an entire biochemical pathway. Using a single targeting gRNA, they achieved integration of up 
to 18 copies of a 24 kb donor construct in a single reaction. Since there are hundreds of copies of 
the δ sequence found in the S. cerevisiae genome [93, 94], this approach is highly scalable. 
However, there is limited control over the number of copies integrated into the genome or where 
in the genome the integration occurs, and so targeting δ sites is not ideal for fine-tuning gene copy 
number and balancing pathway flux. In this regard, the LP platform provides a more systematic 
approach for titrating gene copy number in order to enhance flux towards desired end products. 
 
4.2. Titrating gene expression using the Landing Pad platform 
To ensure that transcription levels correlated with gene copy number in our system, we 
measured gene expression at various genomic loci and selected sites that showed similar 
expression levels (Figure 4D). This was verified by integrating gfp into each LP motif, which 
demonstrated that the configuration we chose for the LP platform facilitated titration of gene 
expression by copy number variation. A positive correlation between gene copy number and gene 
expression was observed for strains containing gfp integrated into the LP copy number motifs 
(Figure 8A). In other words, fluorescence levels increased in proportion to each additional copy of 
gfp introduced into the LP platform. This provides further confirmation that gene expression at 
each LP motif is proportionate to gene copy number, and is not confounded by regional differences 
in transcription levels between genomic loci. 
 
While increasing copy number is an effective way to overcome enzyme inefficiencies, it 
can also be deleterious to the cell beyond a certain threshold. For example, Xie et al. (2015) 
observed increased lycopene titers from engineered lycopene-producing S. cerevisiae strains 
expressing two-copies of CrtI compared to strains expressing one copy of CrtI. However, strains 
expressing three-copies of CrtI produced lower lycopene titers and accumulate less biomass 
compared to the single copy strains. This study illustrates the importance of tuning gene copy 
number to achieve the optimal gene dosage, and also demonstrates that overexpressing genes 
can sometimes have detrimental effects that limit flux through the pathway [24] [91]. On the other 
hand, increasing gene dosage may not influence enzyme efficiency levels at all, and so expressing 
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additional copies of those genes would be energetically wasteful [25]. Considering these factors, 
the LP platform offers a simple strategy for optimizing gene dosage, and testing whether an 
enzyme is responsive to gene dosing or, alternatively, if other interventions are necessary to 
improve efficiency. 
 
4.3. Targeted integration efficiency into the Landing Pad platform 
Though different in design and purpose, the efficiency of multi-loci integration into the LP 
platform is comparable to other multiplexed integration strategies using CRISPR/Cas9 (Table 5). 
Under the initial transformation conditions, integration efficiency into the LP platform varied for 
each copy number motif (Figure 7B). While targeted integration of gfp into LP1 was highly efficient, 
the efficiency of multi-copy gfp integration declined as the number of targeted loci increased. Other 
groups have reported similar reductions in integration efficiency for multi-loci targets. Bao et al. 
(2015) reported 100% efficiency for a single gene disruption using 100 bp donor DNA, and only 
27% efficiency for triple-gene disruption events. Similarly, using the CasEMBLR method, 
Jakočiūnas et al. (2015) achieved 97% efficiency for integration into a single locus, 58% efficiency 
at two loci, and 31% efficiency at three loci. At first glance, the rate of integration reported by 
Jakočiūnas et al. seems comparable to the initial integration efficiencies reported in this study 
(Figure 7B). However, their work also required the assembly of a 5-part donor for each targeted 
integration event (15 parts total), which likely reduced the efficiency that could be obtained using 
pre-assembled donor. Nevertheless, the most convincing evidence to suggest that multi-loci LP 
integration can be achieved at higher efficiencies came from a study by Ronda et al. (2015), who 
integrated three large constructs ranging from 5.1-6.6 kb into three separate loci with 84% 
efficiency [54]. In addition to achieving high multi-loci integration efficiency, this study was also 
notable because large DNA constructs are often more difficult to integrate than smaller DNA 
constructs. This prompted further investigation into how multi-loci integration into the LP platform 
could be optimized to achieve similar efficiencies. 
 
4.4. Improving integration efficiency by propagating cells in selective media 
By sequencing partial integrant colonies, we determined that the efficiency of multi-loci 
integration into the LP platform was ultimately limited by the rate of Cas9-mediated DSB formation. 
We and others have shown that generating DSBs at the target site greatly enhances integration 
efficiency (Figure 3E) [39, 54, 55, 95, 96], and so it is unlikely that integration will occur at any 
targeted integration site that remains intact. Therefore, to increase the efficiency for multi-loci 
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integration using CRISPR/Cas9, it was important to increase the activity of the Cas9-gRNA 
complex in order to generate DSBs at all targeted loci. Based on previous assays, we suspected 
that Cas9-gRNA expression and/or activity was too low to efficiently cleave host DNA at multiple 
loci. Poor performance of the pCAS expression system was likely compounded by the low turnover 
rate observed for Cas9, which remains bound to DNA even after cleavage has occurred [49]. 
 
To overcome the implicit limitations of the CRISPR/Cas9 system used for LP integrations, 
we propagated transformation outgrowth cultures in liquid selection medium over two days and 
achieved nearly 100% integration efficiency into all LP motifs (Figure 7C). This approach was also 
implemented by Bao et al. (2015) and Shi et al. (2016) to improve the efficiency of their respective 
multiplexed CRISPR/Cas9-based strategies. Bao et al. (2015) speculated that continued selective 
pressure to maintain the CRISPR/Cas9 plasmid prolongs cellular exposure to Cas9 nuclease 
activity, and provides more time to generate the necessary DSBs [52]. Due to the lethality of 
unrepaired DSBs, we also suspect that prolonged expression of the Cas9-gRNA complex enriches 
the culture for cells able to repair DSBs using the donor construct supplied in the initial 
transformation (Figure 12). Using LP4 as an example, our rationale is as follows: i) upon 
transformation into LP4, many of the transformants would have contained partial integrations i.e. 
one out of four ‘LP4’ landing pads contained integrated donor DNA, while the other three ‘LP4’ 
landing pads remained untouched; ii) Sequencing also showed that the gRNA and cas9 constructs 
were intact and unmutated, which indicates that they are functional inside the cell; iii) therefore, 
prolonging the exposure of CRISPR/Cas9 machinery means that each LP4 target site that 
remained intact during the initial transformation would eventually be interrogated by Cas9; iv) new 
Cas9-induced DSBs are then repaired by HDR using the donor DNA construct that had integrated 
into the chromosome at an LP4 site during the initial transformation, eventually converting partial 
integrants to full integrants. Chromosomal repair mechanisms inherent to S. cerevisiae [97] likely 
drive HDR of newly generated DSBs using the LP.A and LP.Z recombinogenic regions of intact 
LPs from different loci within the same motif. Complete integration into the LP motif occurs when 
all of the targeted loci have been repaired by LP sites harbouring previously integrated donor DNA. 
Conversely, any cells lacking an integrated donor within the targeted motif will have no mechanism 
to replace the LP target sites to prevent Cas9-induced DSBs in future generations. Therefore, as 
the culture approaches saturation it becomes enriched with cells that have replaced all of the 
target sites with donor DNA. As well, cells unable to replace the target sites with donor DNA will 
be gradually eliminated from the population by Cas9 interrogation. Hence, the majority of cells that 
are plated after the two-day propagation in selective medium will have completed integration at 
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the targeted LP motif. Although this method provides a simple solution for achieving higher 
integration efficiencies into the LP platform, it requires more time to produce the desired results. 




Figure 12. Outgrowth in liquid selection medium improves integration efficiency 
(1) Transformation of donor DNA into LP4 results in partial integration event at a single LP4 locus. (2) Transformants are transferred to medium 
selecting for the pCAS plasmid, resulting in prolonged exposure to Cas9-gRNA for 48h. (3) Continued Cas9-gRNA interrogation induces DSBs at LP4 
loci that remained intact in the initial transformation (3a) Cells unable to repair newly generated DSBs will not survive and will be gradually eliminated 
(3b) Cells able to repair new DSBs by HDR using previously integrated donor DNA will survive. (4) Continued LP4 interrogation by Cas9-gRNA over 
multiple generations will eventually convert partial integrants into full integrants. Once a cell has reached full LP4 integration, there are no target sites 
left for Cas9-gRNA to interrogate. 
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4.5. Optimizing CRISPR/Cas9 expression systems in S. cerevisiae 
CRISPR/Cas9-mediated integration in S. cerevisiae is dependent on two critical processes: 
1) the generation of Cas9-mediated DSBs and 2) subsequent HDR repair of the DSB with donor 
DNA [39]. In our effort to improve multi-loci integration efficiency into the LP platform, it became 
evident that our system was limited by suboptimal DSB generation, presumably caused by low-
activity of the Cas9-gRNA complex. Even though we achieved high integration efficiencies after 
prolonged exposure of cells to the Cas9-gRNA complex, the additional two-day time commitment 
is not ideal for advancing the strain building process. Therefore, further optimization of Cas9-gRNA 
activity is needed to overcome the limitations of our current strategy. This could be accomplished 
by either modifying the existing CRISPR/Cas9 system presently in-use, or by exploring alternative 




The gRNA targeting sequence is a key parameter for all CRISPR/Cas-based engineering 
strategies, and is often the first component that requires optimization. A poorly designed gRNA 
will diminish targeted Cas9 nuclease activity and drastically reduce the efficiency of targeted 
integration [39, 57, 98]. Therefore, multiplexed CRISPR/Cas9-based strategies that use more than 
one gRNA for targeting multiple loci will be only as efficient as their least effective gRNA target 
sequence [53-55]. Our multiplex integration strategy avoids this potential constraint by expressing 
a single, high-functioning synthetic gRNA for multi-loci targeting. Since the target sequences we 
selected for the LP platform demonstrate high targeting specificity (Figure 3D, Figure 5C) and high 
integration efficiency (Figure 3E), it is unlikely that the gRNA target sequences require further 
optimization. However, it is also important to consider the gRNA expression systems used for 
multiplexing, as these systems determine the intracellular availability of the gRNA for guiding Cas9 
to the target sites. Multiplexed CRISPR strategies that use different gRNAs for targeting multiple 
loci typically express the gRNAs from individual expression cassettes cloned into the same 
plasmid [52, 54, 55], or assembled on separate plasmids [53]. Since each gRNA targets a single 
locus, these expression systems likely produce sufficient gRNA levels for guiding Cas9 to all 
targeted loci. For systems such as ours that use a single gRNA expression cassette for targeting 
more than one locus, the demands are less clear. It is possible that the intracellular levels of gRNA 
are too low to reliably guide Cas9 to all of the LP sites within the multi-loci motif, which would 
explain the low efficiency of DSB-induction within our system. However, the pCAS vector used to 
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express the LP gRNAs contains an enhanced gRNA architecture that greatly improves the 
intracellular levels of functional gRNA [28], which may help overcome the higher demands placed 
on gRNAs targeting multiple loci. Nevertheless, further examination into the relationship between 
gRNA availability and efficiency of Cas9-mediated DSB induction is needed to uncover whether 
the gRNA expression levels are rate-limiting in our current system. 
 
Cas9 expression and delivery systems 
Different multiplexed CRISPR/Cas-based strategies have employed various approaches 
for cas9 expression and delivery, including the use of strong constitutive promoters [21, 52, 55, 
82, 99], chromosomal expression of cas9 [53, 54, 99], or using engineered Cas9 enzyme variants 
[21, 52]. Based on the efficiencies reported by other multiplexed CRISPR/Cas9 integration 
strategies, it appears our integration strategy could benefit by expressing cas9 from a high 
strength promoter rather than the medium strength promoter currently employed. During the 
design of the pCAS plasmid, Ryan et al. (2014) showed that high expression of cas9 reduced 
cellular fitness, whereas moderately expressed cas9 maintained wild-type fitness levels [28]. 
However, more recent CRISPR/Cas9-based applications have shown that high cas9 expression 
(–gRNA) does not adversely affect growth rates [54, 55, 82, 99]. Even including studies that used 
a higher functioning Cas9 variant expressed from an ultrahigh copy number plasmid (~200 per 
cell) [21, 52] do not report that Cas9 is detrimental to the cell when expressed without gRNA. 
Nevertheless, the effects of constitutive Cas9 expression over time are still largely unknown, and 
could vary between different strains and CRISPR/Cas9 systems. In this regard, transient 
expression from an episomal plasmid is preferred over chromosomal expression because cas9-
expressing plasmids can be conveniently removed by culturing in non-selective media. Plasmid-
based cas9 expression systems are also associated with higher integration efficiencies [21, 52, 
54, 55] compared to the integration efficiencies achieved when cas9 is expressed from the 
chromosome [53, 54]. This might be explained by copy number differences between the two 
systems, where the cas9 copy number ranges from 1-200 copies using different expression 
vectors, whereas chromosomal cas9 expression is typically from a single copy. Considering the 
wide copy-number range offered by different expression vectors, it is also easier to enhance cas9 
expression levels with plasmid-based systems. This would be especially useful for multiplexed 
strategies that may require high cas9 expression for efficient targeted DSB induction. Further 
improvements could be made by expressing a more active Cas9 nuclease such as the iCas9 
variant used in the HI-CRISPR system [52], or probing other genome editing nucleases. Taken 
together, the results obtained from these strategies indicate that high constitutive expression from 
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an episomal plasmid is the best approach for optimizing intracellular Cas9 levels. Increasing Cas9 
abundance may also necessitate further optimization of gRNA expression such that neither 
component limits the formation or activity of the Cas9-gRNA complex. 
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Table 5. Summary of multiplexed CRISPR/Cas9-mediated integration strategies 
 
a  assembled in vivo 
* gRNA & cas9 delivered on the same plasmid 
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4.6. NCS activity and the effects of gene dosage 
To demonstrate the utility of the LP platform in pathway engineering, we used the system to 
increase gene copy number of ten NCS enzyme orthologs in order to identify the best variant for 
(S)-norcoclaurine synthesis in yeast, and to test whether increasing gene copy number enhances 
production. Ten NCS variants were integrated into the LP platform in 1-4 copies, generating 40 
LP.NCS strains that were then analyzed for production of (S)-norcoclaurine. From this assay, we 
identified six NCS variants that are functional in S. cerevisiae, and demonstrated that increasing 
gene copy number improves the efficiency of some variants to synthesize (S)-norcoclaurine 
(Figure 11C). The most active NCS enzymes identified in this study were NdNCS and ScNCS, 
which produced the highest (S)-norcoclaurine titers from single copy strains. Moreover, 
expressing four copies of either NdNCS or ScNCS generated ~130 µg/L (S)-norcoclaurine, which 
is 20 µg/L more than the highest producing strain that has been reported for de novo synthesis of 
(S)-norcoclaurine [75]. 
 
 Generally, gene dosage effects for the majority of active NCS variants were consistent 
with GFP expression data. Strains expressing four copies of EcNCS, NdNCS, PsNCS3, or ScNCS 
produced two-fold more (S)-norcoclaurine compared to the respective single-copy strains. 
However, unlike the linear relationship observed between gfp copy number and GFP fluorescence 
(Figure 8A), the trends observed for NCS copy number and (S)-norcoclaurine production were not 
entirely linear. For example, varying degrees of improvement in the production levels of (S)-
norcoclaurine were observed for each additional copy of NdNCS expressed in S. cerevisiae; i.e. 
a 66% increase from one to two copies, a 5% increase from two to three copies and a 42% 
increase from three to four copies. However, if the three-copy NdNCS data points are omitted, the 
remaining data generated for the NdNCS strains closely resembles the linear trend observed 
between the ScNCS copy number strains. Considering these variants are nearly identical, it is 
possible that the three-copy NdNCS strains are defective in some way that diminishes the level of 
(S)-norcoclaurine produced and/or detected. Similarly, the production of (S)-norcoclaurine was 
also not proportionate between strains expressing three- and four-copies of PsNCS3. From one- 
to three-copies of PsNCS3, the production of (S)-norcoclaurine increased by 60% for each 
additional copy expressed in yeast, while the strains expressing four copies of PsNCS3 were less 
productive than the three-copy strains. While not directly comparable, a recent study done by Li 
et al. (2016) revealed that some NCS variants from the Papaveraceae family naturally occur as 
tandem fusions consisting of multiple catalytic domains, and demonstrated that enzyme efficiency 
increases in proportion to the number of repeated domains present. Functional expression 
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analysis of strains expressing PsNCS3 variants encoding four catalytic domains showed a 20-fold 
improvement in catalytic efficiency compared to the single domain variant [74]. Although the 
catalytic activities of enzymes expressed as tandem fusions are not exactly analogous to the 
activity of enzymes expressed from multiple gene copies, the results imply that increasing NCS 
copy number can be an effective strategy for enhancing enzyme efficiencies. 
 
However, not all NCS variants that are functional in S. cerevisiae respond to increased copy 
numbers. For instance, titrating the gene dosage of SdNSC and TfNCS did not affect production 
of (S)-norcoclaurine, which remained relatively stable between copy number variants (Figure 
11C). This was unexpected because strains containing SdNCS or TfNCS variants produced more 
(S)-norcoclaurine than PsNCS3 and EcNCS between single-copy strains, and so we would expect 
that increasing gene dosage would affect the efficiency of these variants. In their study, Li et al. 
(2016) also showed that SdNCS was more efficient than PsNCS3 when expressed as a single 
domain protein in S. cerevisiae. However, functional expression of an SdNCS variant encoding 
two catalytic domains only produced marginal improvements in enzyme efficiency compared to 
the multi-domain PsNCS3 variant [74], further suggesting that SdNCS activity is not contingent on 
gene copy number. Moreover, considering that the TfNCS and SdNCS variants are nearly identical 
(Appendix Table A17, Appendix Figure A1), it is conceivable that TfNCS functions in a similar 
manner. Both TfNCS and SdNCS variants contain a predicted chloroplast signalling peptide at 
their C-termini, and so it is possible that they are localized to a membrane that becomes saturated 
at a single copy. Indeed, studies have shown that increasing the copy number of heterologous 
enzymes does not always lead to increases in activity [25, 91, 100]. Differences in translational 
processes or protein folding may present certain limitations on enzyme levels [91, 100], or the 
enzyme levels could be regulated by other mechanisms that prevent accumulation within the cell 
[101]. A study done in Pichia pastoris showed that increasing gene copy number can sometimes 
affect protein folding and disulfide bond formation in the endoplasmic reticulum (ER), and can 
prevent secretion from the ER and cause the nascent protein to accumulate inside the cell [91]. 
Therefore, it is possible that specific properties in the amino acid sequence shared between 
variants SdNCS and TfNCS could have affected the way these proteins are processed in the cell 
and limit their activity in S. cerevisiae. Further investigation into the protein abundance and 
solubility of functional NCS variants may help explain why the activity of some variants correlates 
with gene dosage, while other variants remain unaffected. 
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4.7. Future directions 
This work focused on establishing the LP platform in S. cerevisiae as a system for multi-
copy gene integration, however, the upper limits for copy-number integration into the LP platform 
have not been established. By targeting more than one LP motif in different combinations, the LP 
platform has the potential to facilitate integration of up to ten copies of a gene in a single 
transformation. For example, targeting LP1 and LP4 would generate a five-copy integration, LP2 
and LP4 would generate a six-copy integration, and so on until all four LP motifs are targeted to 
generate a ten-copy integration event. This would not require any new parts, only new 
combinations of gRNAs and donors already used for integration into the LP platform. As well, 
Horwitz et al. (2015) established that it is possible to transform multiple gRNAs as linear cassettes 
for assembly with the same vector backbone, therefore only one selection marker is required for 
expressing the gRNAs and cas9. However, targeting more than one LP motif would likely 
necessitate additional outgrowth in liquid selection media to improve integration efficiency, as we 
observed for the multi-copy integrations targeting each LP motif independently. To further increase 
the efficiency of our integration strategy, we could apply other CRISPR/Cas9 delivery systems, 
such as the HI-CRISPR system developed by Bao et al. (2015) that co-expressed the iCas9 
variant with the gRNA from ultra-high copy number plasmid.  This may circumvent the need for 
the incubation period in liquid selection, though this is uncertain as both Bao et al. (2014) and Shi 
et al. (2016) included this step while using the HI-CRISPR system. 
 
One of the drawbacks of the current LP platform is that it is limited in scale. In our current 
strategy, once a gene has integrated into an LP motif, that motif cannot be targeted for future 
integrations. This makes it difficult to build upon metabolic pathways or optimize the dosage of 
more than one gene in the same strain. It would be useful to fuse a new recombinogenic region 
and synthetic target site to either the 5' or 3' end of the gene construct, so that the LP motifs can 
be recycled for future use. This would extend the utility of the LP platform for building metabolic 
pathways and balancing flux by optimizing expression levels of multiple enzymes. 
 
4.8.  Conclusion 
There is a continuous effort to advance the pathway optimization process in order to 
efficiently build new yeast strains capable of producing high-value bio-based chemicals. The LP 
platform presented in this work supports these efforts by providing a simple and efficient strategy 
for marker-less, multi-copy gene integration in S. cerevisiae using the CRISPR/Cas9 genome 
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editing system. We demonstrated the utility of the LP platform for titrating gene expression by 
integrating different copy number variations in a single step, which permits the rapid testing of 
gene dosage effects on enzyme efficiency for pathway optimization. As proof-of-concept, we used 
the LP platform to titrate gene copy number of ten NCS enzyme variants in order to improve 
production of (S)-norcoclaurine in yeast, the entry point into BIA metabolism and a major 
bottleneck. The LP platform facilitated the discovery of two NCS enzyme variants that exhibited 
higher activity levels and enhanced efficiencies by increasing gene dosage. Given the efficacy for 
integrating multiple gene copies and enhancing gene expression, the LP platform provides a 
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Table A1. Strains used in this work 




Integrant Locus AN 
Parent 
strain 
CENPK2-1D – – 
MATα; leu2-3,112 ; ura3-




LP1.T1 LP1.T1 FgF20 CENPK2-1D This study 
LP1.T2 LP1.T2 FgF20 CENPK2-1D This study 
LP1.T3 LP1.T3 FgF20 CENPK2-1D This study 
LP1.T4 LP1.T4 FgF20 CENPK2-1D This study 
LP1.T5 LP1.T5 FgF20 CENPK2-1D This study 
LP1.T6 LP1.T6 FgF20 CENPK2-1D This study 
LP1.T7 LP1.T7 FgF20 CENPK2-1D This study 
LP1.T8 LP1.T8 FgF20 CENPK2-1D This study 
LP1.T9 LP1.T9 FgF20 CENPK2-1D This study 
LP1.T10 LP1.T10 FgF20 CENPK2-1D This study 
LP1.T3. 
SiteX 
LP1.T3-FgF1 LP1.T3 FgF1 CENPK2-1D This study 
LP1.T3-FgF5 LP1.T3 FgF5 CENPK2-1D This study 
LP1.T3-FgF7 LP1.T3 FgF7 CENPK2-1D This study 
LP1.T3-FgF8 LP1.T3 FgF8 CENPK2-1D This study 
LP1.T3-FgF11 LP1.T3 FgF11 CENPK2-1D This study 
LP1.T3-FgF12 LP1.T3 FgF12 CENPK2-1D This study 
LP1.T3-FgF14 LP1.T3 FgF14 CENPK2-1D This study 
LP1.T3-FgF16 LP1.T3 FgF16 CENPK2-1D This study 
LP1.T3-FgF18 LP1.T3 FgF18 CENPK2-1D This study 
LP1.T3-FgF19 LP1.T3 FgF19 CENPK2-1D This study 
LP1.T3-FgF20 LP1.T3 FgF20 CENPK2-1D This study 
LP1.T3-FgF21 LP1.T3 FgF21 CENPK2-1D This study 
LP1.T3-FgF22 LP1.T3 FgF22 CENPK2-1D This study 
LP1.T3-FgF23 LP1.T3 FgF23 CENPK2-1D This study 
LP1.T3-FgF24 LP1.T3 FgF24 CENPK2-1D This study 
LP1.T3-UserXII-1 LP1.T3 UserXII-1 CENPK2-1D This study 
LP1.gfp. 
SiteX 
LP1. gfp -FgF1 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF1 This study 
LP1. gfp -FgF5 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF5 This study 
LP1. gfp -FgF7 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF7 This study 
LP1. gfp -FgF8 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF8 This study 
LP1. gfp -FgF11 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF11 This study 
LP1. gfp -FgF12 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF12 This study 
LP1. gfp -FgF14 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF14 This study 
LP1. gfp -FgF16 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF16 This study 
LP1. gfp -FgF18 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF18 This study 
LP1. gfp -FgF19 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF19 This study 
LP1. gfp -FgF20 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF20 This study 
LP1. gfp -FgF21 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF21 This study 
LP1. gfp -FgF22 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF22 This study 
LP1. gfp -FgF23 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF23 This study 
LP1. gfp -FgF24 pTDH3- gfpS65T -tCYC1 LP1.T3 LP1.T3-FgF24 This study 
LP1. gfp -UserXII-1 pTDH3-gfpS65T-tCYC1 LP1.T3 LP1.T3-UserXII-1 This study 







UserXII-1; FgF7; FgF19 
FgF12; FgF16; FgF21; FgF22; 




LP1-gfp pTDH3- gfpS65T -tCYC1 LP1 [FgF20] CEN.10xLP This study 
LP2- gfp pTDH3- gfpS65T -tCYC1 LP2 [FgF18; FgF24] CEN.10xLP This study 
LP3- gfp pTDH3- gfpS65T -tCYC1 LP3 [UserXII-1; FgF7; FgF19] CEN.10xLP This study 









URA3 BY4741/MATα; Met- His- 
[75] 
AN:KR232306 
CEN.10xLP.D ARO4 CEN.10xLP This study 
LP-NCS 
Strains 
LP1-AmNCS AmNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-AmNCS AmNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-AmNCS AmNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-AmNCS AmNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-EcNCS EcNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-EcNCS EcNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-EcNCS EcNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-EcNCS EcNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-NdNCS NdNCS LP1 {FgF20} CEN.10xLP.D This study 
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LP2-NdNCS NdNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-NdNCS NdNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-NdNCS NdNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-PsNCS1 PsNCS1 LP1 {FgF20} CEN.10xLP.D This study 
LP2-PsNCS1 PsNCS1 LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-PsNCS1 PsNCS1 LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-PsNCS1 PsNCS1 LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-PsNCS2 PsNCS2 LP1 {FgF20} CEN.10xLP.D This study 
LP2-PsNCS2 PsNCS2 LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-PsNCS2 PsNCS2 LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-PsNCS2 PsNCS2 LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-PsNCS3 PsNCS3 LP1 {FgF20} CEN.10xLP.D This study 
LP2-PsNCS3 PsNCS3 LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-PsNCS3 PsNCS3 LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-PsNCS3 PsNCS3 LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-ScNCS ScNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-ScNCS ScNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-ScNCS ScNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-ScNCS ScNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-SdNCS SdNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-SdNCS SdNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-SdNCS SdNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-SdNCS SdNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-TcNCS TcNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-TcNCS TcNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-TcNCS TcNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 
LP4-TcNCS TcNCS LP4 {FgF12; FgF16; FgF21; FgF22} CEN.10xLP.D This study 
LP1-TfNCS TfNCS LP1 {FgF20} CEN.10xLP.D This study 
LP2-TfNCS TfNCS LP2 {FgF18; FgF24} CEN.10xLP.D This study 
LP3-TfNCS TfNCS LP3 {UserXII-1; FgF7; FgF19} CEN.10xLP.D This study 




Table A2. Plasmids used in this work 




Ryan et al. (2014) 
 Addgene #60847 





pCas-Tyr-gRNA1 gRNA1 is targeted to T1 This study 
pCas-Tyr-gRNA2 gRNA2 is targeted to T2 This study 
pCas-Tyr-gRNA3 gRNA3 is targeted to T3 This study 
pCas-Tyr-gRNA4 gRNA4 is targeted to T4 This study 
pCas-Tyr-gRNA5 gRNA5 is targeted to T5 This study 
pCas-Tyr-gRNA6 gRNA6 is targeted to T6 This study 
pCas-Tyr-gRNA7 gRNA7 is targeted to T7 This study 
pCas-Tyr-gRNA8 gRNA8 is targeted to T8 This study 
pCas-Tyr-gRNA9 gRNA9 is targeted to T9 This study 
pCas-Tyr-gRNA10 gRNA10 is targeted to T10 This study 
GC975 
CEN6/ARS4ori, pMB1ori, HIS3, bla, loxP-kanMX, pTDH3-GFP_S65T-
TCYC1 




Deloache et al. (2015) 
KR232306.1 
pBOT(his3)_ AmNCS pTEF1-AmNCS-tPGI1 This study 
pBOT(his3)_ EcNCS pTEF1-EcNCS-tPGI1 This study 
pBOT(his3)_ NdNCS pTEF1-NdNCS-tPGI1 This study 
pBOT(his3)_ PsNCS1 pTEF1-PsNCS1-tPGI1 This study 
pBOT(his3)_ PsNCS2 pTEF1-PsNCS2-tPGI1 This study 
pBOT(his3)_ PsNCS3 pTEF1-PsNCS3-tPGI1 This study 
pBOT(his3)_ ScNCS pTEF1-ScNCS-tPGI1 This study 
pBOT(his3)_ SdNCS pTEF1-SdNCS-tPGI1 This study 
pBOT(his3)_ TcNCS pTEF1-TcNCS-tPGI1 This study 




LANDING PAD CONSTRUCTS 
Table A3. Landing Pad sequences with assigned target sites 
ID 
Sequence 














































PRIMERS USED IN THIS WORK 
Table A4. Primers to linearize pCAS backbone & gRNA cassette 
ID Sequence Description 
GC2946_pCAS_F TAGGTCTAGAGATCTGTTTAGCTTG 
Amplifies pCAS vector backbone 
from 5' RNR2p 
GC2947_pCAS_R GCATTTAAGCATAAACACGC 
Amplifies pCAS vector backbone 
from 3' 2µ ori 
LB33_HDV_gRNA_F CACCTATATCTGCGTGTTGC Universal gRNA forward 
GC2894_HDV_gRNA_R AAAGTCCCATTCGCCACC Amplifies HDV blunt left 
GC2895_gRNA_scaffold_F GTTTTAGAGCTAGAAATAGCAAGT Amplifies scaffold blunt right 
LB34_gRNA_scaffold_R GTCAAGACTGTCAAGGAGG Universal gRNA reverse 
 
Table A5. Primers to program synthetic gRNAX construct into pCAS 




Scaffold_F with gRNA1 5' overhang 




Scaffold_F with gRNA2 5' overhang 




Scaffold_F with gRNA3 5' overhang 




Scaffold_F with gRNA4 5' overhang 




Scaffold_F with gRNA5 5' overhang 




Scaffold_F with gRNA6 5' overhang 




Scaffold_F with gRNA7 5' overhang 




Scaffold_F with gRNA8 5' overhang 




Scaffold_F with gRNA9 5' overhang 




Scaffold_F with gRNA10 5' overhang 




Table A6. Primers to program the gRNAs targeting genomic loci for LP1. T3 integrations 















































































#1 FF229_FgF23.gRNA.1_scaff_F CTTCTTTGCGATACGTCTTAgttttagagctagaaatagcaagt 
FF230_FgF23.gRNA.2_3'HDV_R AGGTATTTGGTAACAACAAGaaagtcccattcgccacc 





#1 FF167_FgF24.gRNA.1_3'HDV_R CGTAAATCTTGTCCAATAGGaaagtcccattcgcc 
FF168_FgF24.gRNA.2_scaff_F ATTTCGTTGTACTCTGCGTGgttttagagctagaaatagcaagt 





2 SB79_USERXII-1.gRNA2.AS GATGGGTAACCGGCAAAGACaaagtcccattcgccacc 
LB679-ARO4-gRNA11.S GCTTAGTAACACCCATGAAAgttttagagctagaaatagcaagt 
GCTTAGTAACACCCATGAAA ARO4 
LB680-ARO4-gRNA11.AS  TTTCATGGGTGTTACTAAGCaaagtcccattcgcc 
 
Table A7. Primers to amplify Landings Pads 
ID Sequence Description 
LB1_LP1.A_F CGAGAACCTCAGTTACTTTTC amplifies LP1.A at 5' end 
LB4_LP1.Z_R TTGTTTATGGACACGGC amplifies LP1.Z at 3' end 
FF346_LP2.A_F TGCTCCAAGTGTGTGACTCC amplifies LP2.A at 5' end 
FF347_LP2.Z_R GCTTCAAAGACGTGAGTGTGC amplifies LP2.Z at 3' end 
FF348_LP3.A_F CGCATAGACATACAAGTGGACAG amplifies LP3.A at 5' end 
FF349_LP3.Z_R GAATGGTATTCTGAAGCTGCAC amplifies LP3.Z at 3' end 
FF350_LP4.A_F CAATGGAGCTCGCAATACAG amplifies LP4.A at 5' end 





























































































Table A8. Primers to build LP1.TX constructs 
ID Sequence Description 
target1_LP1.Z_F CTAGATAAGACGTGGCAGATCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T1 overhang 
LP1.A_target1_R CCGATCTGCCACGTCTTATCTAGgcatttttattatataagttgttttatt Amplifies LP1.A with T1 overhang 
target2_LP1.Z_F CCACCGCTCAGTAGCGGCTTCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T2 overhang 
LP1.A_target2_R CCGAAGCCGCTACTGAGCGGTGGgcatttttattatataagttgttttatt Amplifies LP1.A with T2 overhang 
target3_LP1.Z_F GCCAGTCAGAACACTAGAGGCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T3 overhang 
LP1.A_target3_R CCGCCTCTAGTGTTCTGACTGGCgcatttttattatataagttgttttatt Amplifies LP1.A with T3 overhang 
target4_LP1.Z_F ACGCCGTTTTTCACATCTGTCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T4 overhang 
LP1.A_target4_R CCGACAGATGTGAAAAACGGCGTgcatttttattatataagttgttttatt Amplifies LP1.A with T4 overhang 
target5_LP1.Z_F GATACAACCCATCCGCGCTACGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T5 overhang 
LP1.A_target5_R CCGTAGCGCGGATGGGTTGTATCgcatttttattatataagttgttttatt Amplifies LP1.A with T5 overhang 
target6_LP1.Z_F ACGTGTCATACGAGGTATAGCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T6 overhang 
LP1.A_target6_R CCGCTATACCTCGTATGACACGTgcatttttattatataagttgttttatt Amplifies LP1.A with T6 overhang 
target7_LP1.Z_F ATTGTACCCCAGCGGCGGCGCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T7 overhang 
LP1.A_target7_R CCGCGCCGCCGCTGGGGTACAATgcatttttattatataagttgttttatt Amplifies LP1.A with T7 overhang 
target8_LP1.Z_F TAAGTCCGCGGATAACCATTCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T8 overhang 
LP1.A_target8_R CCGAATGGTTATCCGCGGACTTAgcatttttattatataagttgttttatt Amplifies LP1.A with T8 overhang 
target9_LP1.Z_F GTAGCCCAACAGGAGCACATCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T9 overhang 
LP1.A_target9_R CCGATGTGCTCCTGTTGGGCTACgcatttttattatataagttgttttatt Amplifies LP1.A with T9 overhang 
target10_LP1.Z_F TCCCCAATCGTGGAGTGAAGCGGcctctttatattacatcaaaataaga Amplifies LP1.Z with T10 overhang 
LP1.A_target10_R CCGCTTCACTCCACGATTGGGGAgcatttttattatataagttgttttatt Amplifies LP1.A with T10 overhang 
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Table A9. Primers to construct LP1.T3.SiteX donors 










16 5' homology to LP1.Z, 3' overhang to FgF site 
FgF1.Up_LP1.A_F 
AGCACAGTGAcgagaacctcagttactttt 
1 5' overhang to FgF site, 3' homology to LP1.A 
FgF1.D_LP1.Z_R GCCATATTTCTGAttgtttatggacacggc 1 5' homology to LP1.Z, 3' overhang to FgF site 
FgF5.up_LP1.A_F 
TAGAAGCAcgagaacctcagttactttt 




5 5' homology to LP1.Z, 3' overhang to FgF site 
FgF7.up_LP1.A_F 
AGGGTCCAcgagaacctcagttactttt 








8 5' overhang to FgF site, 3' homology to LP1.A 
FgF8.D_LP1.A_F 
CAAGACAGCcgagaacctcagttactttt 
8 5' homology to LP1.Z, 3' overhang to FgF site 
FgF11.up_LP1.A_F CGTAAAAGTGcgagaacctcagttactttt 11 5' overhang to FgF site, 3' homology to LP1.A 
FgF11.D_LP1.Z_R 
TAATAAGTACTCATttgtttatggacacggc 
11 5' homology to LP1.Z, 3' overhang to FgF site 
FgF12.up_LP1.Z_R TCAGCCGGCTAAGttgtttatggacacggc 12 5' overhang to FgF site, 3' homology to LP1.A 
FgF12.D_LP1.A_F 
AGACGGGGGAcgagaacctcagttactttt 
12 5' homology to LP1.Z, 3' overhang to FgF site 
FgF14.up_LP1.A_F TCTTACACCcgagaacctcagttacttttc 14 5' overhang to FgF site, 3' homology to LP1.A 
FgF14.D_LP1.Z_R 
CGGTTGCATTTTCttgtttatggacacggc 
14 5' homology to LP1.Z, 3' overhang to FgF site 
FgF18.up_LP1.A_F AACTCATGCCcgagaacctcagttactttt 18 5' overhang to FgF site, 3' homology to LP1.A 
FgF18.D_LP1.Z_R 
GGGGACGATTttgtttatggacacggc 
18 5' homology to LP1.Z, 3' overhang to FgF site 
FgF19.up_LP1.A_F CGCGAAcgagaacctcagttactttt 19 5' overhang to FgF site, 3' homology to LP1.A 
FgF19.D_LP1.Z_R 
TGATAGTTGGTCCttgtttatggacacggc 
19 5' homology to LP1.Z, 3' overhang to FgF site 
FgF20.up_LP1.A_F ATCGCAAAcgagaacctcagttactttt 20 5' overhang to FgF site, 3' homology to LP1.A 
FgF20.D_LP1.Z_R 
GACCTTCCATTttgtttatggacacggc 
20 5' homology to LP1.Z, 3' overhang to FgF site 
FgF21.up_LP1.A_F CCTTGGAAcgagaacctcagttactttt 21 5' overhang to FgF site, 3' homology to LP1.A 
FgF21.D_LP1.Z_R 
CTGACGTCCCATCttgtttatggacacggc 
21 5' homology to LP1.Z, 3' overhang to FgF site 
FgF22.up_LP1.A_F ATCCTAGTCCcgagaacctcagttactttt 22 5' overhang to FgF site, 3' homology to LP1.A 
FgF22.D_LP1.Z_R 
ATATGCTTCCCttgtttatggacacggc 
22 5' homology to LP1.Z, 3' overhang to FgF site 
FgF23.up_LP1.A_F CCATTCCCTTcgagaacctcagttactttt 23 5' overhang to FgF site, 3' homology to LP1.A 
FgF23.D_LP1.Z_R 
GTTTTTTGATGATttgtttatggacacggc 
23 5' homology to LP1.Z, 3' overhang to FgF site 
FgF24.up_LP1.Z_R GCGACTTCAACttgtttatggacacggc 24 5' homology to LP1.Z, 3' overhang to FgF site 
FgF24.D_LP1.A_F 
GGTGATCCcgagaacctcagttactttt 


















Table A10. Primers to amplify genomic sites (up/down) with homology to LP1 
ID Sequence Description 
FF31_FgF 16 up_F TCCGTTAATTCGGGTT 
16 up 
FF32_FgF 16 up_R tccgttaattcgggtt 
FF33_FgF 16 down_F TGCCTACGCAACACTT 
16 down 
FF34_FgF 16 down_R TTGTTGGGATTCCATTG 





FF38_FgF 1 down_R aaggtttgtcacgagca 





FF42_FgF 5 down_R GTACACGCTTTGGGG 





FF46_FgF 7 down_R TTGTTGGCATTCCATT 
FF47_FgF8up_LP1.Z_F cttgaagccgtgtccataaacaaACAAACAGGGCAAATCA 
8 up 
FF48_FgF 8 up_R AAAGAACCAGAATGGCA 
FF49_FgF 8 down_F AGCGTTCGTTCTATGC 
8 down 
FF50_FgF8down_LP1.A_R tgaggttctcgGCTGTCTTAGTTAGCTTCG 





FF54_FgF 11 down_R CACTTTTACGCCTCTGCTGA 
FF55_FgF12up_LP1.Z_F tgtccataaacaaCTTAGCCGGCTGAATAA 
12 up 
FF56_FgF 12 up_R GCCGCTCGTAAAAAC 
FF57_FgF 12 down_F TCAACAATGTCGCTTCC 
12 down 
FF58_FgF12down_LP1.A_R gaggttctcgTCCCCCGTCTTTCTT 





FF62_FgF 14 down_R GCCGTCCTCATGATG 





FF66_FgF 18 down_R AAAGCTGGCTCCCCTTAGAC 





FF70_FgF 19 down_R CGTGATAAACGATCGC 





FF74_FgF 20 down_R ATAAAGCAGCCGCTACC 





FF78_FgF 21 down_R TCAAGACACTCCGGTATTAC 





FF82_FgF 22 down_R GGAAACGCTGCCC 





FF86_FgF 23_R CGAGATAAGGCATGGG 
FF87_FgF24up_LP1.Z_F gtccataaacaaGTTGAAGTCGCCTGG 
24 up 
FF88_FgF 24 up_R CTTTCAAGGGTGGGG 




Table A11. Primers to amplify the LP donors  
ID Sequence 



















Attach LP2.A homology 
to TDH3p 











Attach LP3.A homology 
to TDH3p 











Attach LP4.A homology 
to TDH3p 
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Attach LP4.Z homology 
to CYC1t 
TDH3p_F TCGAGTTTATCATTATCAATACTGC gfp 5' end of TDH3p blunt 

















































Attach LP4.Z homology 
to PGI1t 
FF330_Tef1p_F GGACTTTTAATTTTCGAGGAC NCS 5' end of TEF1p blunt 
FF331_Pgi1t_R GGTATACTGGAGGCTTCATG NCS 3' end of PGIt blunt 
 
Table A12. Primers for building dopamine production strain 
ID Sequence Description 
LB75-delARO4up.S GTGACACAAAAACAAAATCGAAAAC 





Amplify half of dopamine production 
cassette from WCD2249 to attach to 






Amplify half of dopamine production 
cassette from WCD2249 to attach to 




ARO4 DOWN homology 
LB82-delARO4down.AS GTGATTTCACCAGTTGTACTTCGT 
 
Table A13. Colony PCR primers to screen for integration at selected genomic loci 





















































Table A14. Multiplex colony PCR primers to screen LP platform integrations 



















































































































































































Table A17. Sequence identity between NCS variants 
 AmNCS EcNCS NdNCS PsNCS1 PsNCS2 PsNCS3 ScNCS SdNCS TcNCS TfNCS 
AmNCS – 37% 35% 47% 35% 36% 35% 36% 39% 37% 
EcNCS 37% – 49% 38% 47% 63% 57% 71% 60% 73% 
NdNCS 35% 49% – 39% 56% 54% 91% 56% 58% 57% 
PsNCS1 47% 38% 39% – 40% 38% 41% 40% 42% 42% 
PsNCS2 35% 47% 56% 40% – 52% 53% 54% 60% 51% 
PsNCS3 36% 63% 54% 38% 52% – 57% 78% 57% 74% 
ScNCS 35% 57% 91% 41% 53% 57% – 60% 60% 61% 
SdNCS 36% 71% 56% 40% 54% 78% 60% – 62% 90% 
TcNCS 39% 60% 58% 42% 60% 57% 60% 62% – 61% 





PSNCS2          --------------------------------------------------------MKYQ 
TCNCS           ------------------------------------------------------------ 
NDNCS           -------------------------------------------MRSGIVFLVLFFLGCEI 
SCNCS           -------------------------------------------MRSGIVFLVLFFLGCEI 
PSNCS3          ------------------------------------------------------------ 
ECNCS           MIGGFLDMGCTFYMDRIHVVAKGPNSCIIKSTLIYEVKEEYADAMASLITVEPLASMAEV 
SDNCS           ------------------------------------------------------------ 
TFNCS           ------------------------------------------------------------ 
AMNCS           -------------------------------------------------MIFTVYILYYK 
PSNCS1          ------------------------------------------------------------ 
 
 
PsNCS2          AGLSIFLLFLIGTGESSKYTLVNDFNVAASADEVWAVYSSHNLPKLIVK-LLPGMFKRID 
TcNCS           ----------------MRKELRHELKVPASADDVWEVYSSPDLPKLIVQ-LLPSVFEKIE 
NdNCS           SQGRQLLESRLFRKSTIRKVLHHELSVAASAQEVWDVYSSPELPKHLPE-ILPGAFKKV- 
ScNCS           SQGRQLLESRLFRKSTIQKVLHHELPVAASAQEVWDVYSSPELPKHLPE-ILPGAFEKV- 
PsNCS3          ----------------MRKVIKYDMEVAVSADSVWAVYSSPDIPRLLRDVLLPGVFEKLD 
EcNCS           VANYVLHQQVRVLGSVKRKELTHELEVAAPADAIWGVYSSPDIPRLLRDVLLPGVFEKLE 
SdNCS           ----------------MRKEVRYEMEVPTSADSIWAVYSSHDIPRLLKEVLLPGVFEKLD 
TfNCS           ----------------MRKELTHEMEVPASADAIWAVYGSPDIPRLLKEVLLPGVFEKLD 
AmNCS           YTTHTANLFRKHIRLKMVASVSGEVEVNAPASKVWELYRSLELLRITKK-GLDHIVDKIE 
PsNCS1          ----------------MKGKISKEVQVPVPASDLWAVYGTLELIRLIKK-LLPEILRDFE 
                                    :  :. * ..*. :* :* : :: .   .  *   .  .  
 
PsNCS2          VLKGDGGVGTILRLVYPPGSVPLT-YKEKFVTIDNRRRLKEVLQIEGGYLKMGVTFYMDS 
TcNCS           VVEGDGGVGTVLHITFPPGSIPIS-YKEKFVTVDDYKRLKEVRQIEGGYLDMGCTFYMDS 
NdNCS           VVTGDGGVGTVIEMIFPPGVVPHR-YKEKFVLIDDEKFLKKVEMIEGGYLDMGCTFYMDT 
ScNCS           VVTGDGGVGTVLEMVFPPGEVPRS-YKEKFVLIDDEQLLKKVEMIEGGYLDMGCTFYMDT 
PsNCS3          VIEGNGGVGTVLDIVFPPGAVPRS-YKEKFVNIDREKRLKEVIMIEGGYLDMGCTFYLDR 
EcNCS           VIQGNGGVGTVLEIVFHPGAIPRR-YKEKFVTINHKKRLKEVVMI-GGYLDMGCTLYMDR 
SdNCS           VIEGDGGVGTVLDIAFPPGAVPRT-YKEKFVTINHEKRLKEVIMIEGGYLDMGCTFYMDR 
TfNCS           VIEGDGGVGTVLDIAFPPGAVPRA-YKEKFMKVNHEKRLKEVEMIEGGYLDMGCTFYMDR 
AmNCS           VLEGDGSVGTLLHFTFHPGALPFSSYKEKFTKVDDENMVKVVEVVEGGFLELGFKWYLVR 
PsNCS1          VVVGDGGVGTVLKLTFPPES-PVTNYSEKFTKVDNEKRIKVTEVVEGGYLEVGFSLYRVT 
                *: *:*.***:: : : *   *   *.***  ::  . :* .  : **:*.:* . *    
 
PsNCS2          FQVIKRGRDSCIIRSITKYEIRDDLAVKVSPLISVDSLVTMARAISKYVLEN-KK----- 
TcNCS           FHILEECHDSCVIVSKTEYEVPQELAANVEPYISIDSLAGMATAISNYVVDK-NK---NK 
NdNCS           IQIIPTGPDSCIIKSSTEYYVKPEFADKVVPLISTVPLQAMAEAIAKIVLEN-KA----- 
ScNCS           IQIVPTGPDSCIIKSSTEYYVKPEFADKVVPLISTIPLQAMAEAISNIVLAN-KA----- 
PsNCS3          IHVVEKTKSSCVIESSIVYDVKEECADAMSKLITTEPLKSMAEVISNYVIQK-ELFSARN 
EcNCS           IHVVSKGPNSCVIKSTLIYEVKAESADAMASTITIDPLASMAQVISNYVLKN-QM----Q 
SdNCS           IHVLEKGPNSCVIESAIIYEVKEEFADVVVPLITTEPLASMAEVISNYVLKK-QI----H 
TfNCS           IHVVEKGPNACVIESAIIYEVKDEFADVVVPLITTEPLASMAEVISNYVLKN-QF----R 
AmNCS           LDVIVKDEKSCITKNTIEYELKEDADPKLASVVSIDPLMAMMNIAANHVVSGIKA----- 
PsNCS1          YEITEKGEHSSVII-TIEYELDDAFADN-ASLVSIKPLQVIAKTIGKYLTEK-KG----- 
                  :      :.:      * :           ::  .*  :    .: :    :       
 
PsNCS2          -----------KANSTIVP----------------------------------------- 
TcNCS           ECEPEGCCDDERDHCSEKEGRHEQSSDESES-------------DCESESDCD------- 
NdNCS           ---------KHKGFIEI------------------------------------------- 
ScNCS           ---------KNKSIIIEI------------------------------------------ 
PsNCS3          ILSKQSVVKKEIRYDLEVPISVDSIWSVY---------------SCPDIPRLL------- 
EcNCS           VLG--SVKRRELTHELEVAASADAIWGVYGSKRYSKASQGCFASWCFRKVRSH------- 
SdNCS           VFG--YVIKPKLGLSLLL----------------------CFI-LCLVLLGVLLIGGVPL 
TfNCS           VFG--YVIKPKLGLSLLL----------------------CFI-LCLVLLGGLLIGGVPL 
AmNCS           ------------------------------------------------------------ 
PsNCS1          ------------------------------------------------------------ 
 
Figure A1. Amino acid sequence alignment of NCS variants 
Alignment generated by MUSCLE (EMBL-EBI). Active enzymes are indicated by red font. Residues are 
colour-coded based on their physicochemical properties: small/hydrophobic (red), acidic (blue), basic 
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(magenta), hydroxyl/sulfhydryl/amine (green), and other (grey). Asterisks indicate fully conserved residues, 




Figure A2. Growth of LPX.NCS variant & copy number strains.  
Cultures were grown in the Sunrise® absorbance microplate reader at 30°C with shaking at 200 rpm. Cell 
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